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Jeremiah 29: 11 “For I know the plans I have for you”, declares the Lord, “plans 














Beclin 1 is a haploinsufficient tumor suppressor gene that is monoallelically 
deleted or epigenetically silenced in multiple human tumor types. In human 
breast cancer, 40% of tumors exhibit monoallelic deletion of Beclin 1. 
Additionally, low Beclin 1 mRNA expression is more commonly observed in ER 
negative (ER-) tumors (HER2 and basal-like subtypes) than ER+ luminal tumors 
and reduced expression is an independent predictor of overall patient survival. 
Previous studies have implicated a role for Beclin 1 in breast cancer progression. 
For example, heterozygous loss of Beclin 1 in mice results in mammary 
tumorigenesis following parity. Furthermore, overexpression of Beclin 1 in an 
orthotopic xenograft model reduces tumor growth. The role of Beclin 1 in cancer 
has almost exclusively been attributed to its function in autophagy. However, 
recent work from our lab demonstrated an alternative role for Beclin 1 in the 
regulation of growth factor receptor trafficking and signaling in vitro that could 
contribute to cancer.  More knowledge of the role of Beclin 1 in breast cancer is 
necessary to understand its mechanism of action and to develop novel 
therapeutic approaches for patients with aggressive disease. Therefore, the 
major objective of my thesis project was to understand the molecular basis by 
which Beclin 1 contributes to breast cancer tumor growth and progression in vivo. 
 
Using in vivo models, I discovered that Beclin 1 promotes endosomal recruitment 
of hepatocyte growth factor tyrosine kinase substrate (HRS), which is necessary 
	 x	
for sorting receptors to intraluminal vesicles for signal silencing and degradation. 
Beclin 1-dependent recruitment of HRS results in the autophagy-independent 
regulation of endocytic trafficking and degradation of the epidermal growth factor 
(EGFR) and transferrin (TFR1) receptors.  When Beclin 1 expression is low, 
endosomal HRS recruitment is reduced and receptor function is sustained to 
drive tumor proliferation.  An autophagy-independent role for Beclin 1 in 
regulating tumor metabolism was also observed. Collectively, my results 
demonstrate a novel role for Beclin 1 in impeding tumor growth by coordinating 
the regulation of growth promoting receptors. These data provide an explanation 
for how low levels of Beclin 1 facilitate tumor proliferation and contribute to poor 
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Rev Mol Cell Biol. 2018 July 19 (579-593) The Macroautophagy Process. 
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Lysosome via MVB Formation Copyright 2007, with permission from Springer 
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Beclin 1 and its Functional Complexes 
Bcl-2-interacting myosin-like coiled-coil protein (Beclin 1) is a 60 KD protein that 
is the mammalian orthologue to yeast Atg6/Vps30 that was first identified through 
a yeast two-hybrid screen for its role in viral protection1. The Beclin 1 protein 
consists of 450 amino acids that form multiple domains. These domains include a 
BCL-2 binding domain, coiled-coil domain (CCD), evolutionary conserved domain 
(ECD) and a nuclear export signal (NES) (Figure 1.1A). Each domain is 
important for mediating interactions between Beclin 1 and multiple interacting 
partners. The CCD and ECD are important for interacting with binding partners 
that mediate Beclin 1’s biological functions. The NES motif of Beclin 1 promotes 





Beclin 1 functions in two main complexes that are mutually exclusive but contain 
the same core complex (Figure 1.1B)3-5. This core complex consists of Beclin 1, 
the lipid kinase class III phosphatidylinositol-3 kinase PI3KC3 (mammalian 
homologue to yeast Vps34), and the regulatory element p150 (mammalian 
homologue to yeast Vps15)6.  PI3KC3 interacts with and is activated by Beclin 1 
through its evolutionary conserved domain (ECD)7. PI3KC3 is member of a 
kinase family that phosphorylates inositols to generate 3-phosphoinositides8. 
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Beclin 1 binds and activates the kinase activity of PI3KC3 to generate 
phosphatidylinositol 3-phosphate (PI3P), a lipid product that facilitates multiple 
membrane fusion events8,9. ATG14 and UV irradiation resistance-associated 
gene (UVRAG) interact with this core complex by binding the coiled-coil domain 
(CCD) of Beclin 1. These two proteins bind the same domain of Beclin 1 but 
never at the same time; therefore they form mutually exclusive complexes and 
these complexes mediate the distinct functions of Beclin 1 (Figure 1.1B).   
 
Complex I-ATG14 
In Complex I, Beclin 1 interacts with ATG14L (mammalian homologue to yeast 
Atg14) by heterodimerizing with its CCD. ATG14L binding to Beclin 1 has been 
shown to initiate autophagy, one of Beclin 1’s well known functions. Originally 
discovered in yeast, Atg14 was found to be indispensable for autophagy in yeast 
strains10. ATG14L also helps localize this core complex to the endoplasmic 
reticulum and phagophore11. Additionally, ATG14L is important for targeting this 
core complex to membrane curvatures because it contains an intrinsic domain 
which allows it to sense PI3P rich membranes12. Because of the known role of 
ATG14L in autophagy, ATG14L is also known as Beclin-1 associated autophagy 
related key regulator or BARKOR. Recent studies show that Dapper1, a protein 
that helps target Dishevelled to lysosomes to inhibit WNT signaling, is important 
for regulating the ATG14L interaction with Beclin 1 and PI3KC3 to promote 
autophagy13. Overexpression of Dapper 1 in HEK293T cells was shown to  
Complex I Complex II 
Autophagy  Endocytic Receptor Trafficking 
Cytokinesis 
Phagocytosis 
Vacuolar Protein Sorting in Yeast 
B 
A 
Figure 1.1. Schematic of Beclin 1 and its Complexes. (A) Beclin 1 is a 450 
kd protein that consist of multiple domains which mediate its function. Beclin 1 
contained a BH3 domain, a coiled-coil domain (CCD) which interacts with 
ATG14L or UVRAG, an evolutionary conserved domain (ECD) which interacts 
with PI3KC3 and a nuclear export sequence. Protein schematic was 
generated with DOG 1.0 software (Cell Research (2009) 19: 271-273) (B) 
Beclin 1 functions in two mutually exclusive complexes with the binding 
partners ATG14L and UVRAG. These two independent complexes mediate 
Beclin 1’s functions. Figure adapted from Wirawan et al55.	
PI3KC3 
p150 
Beclin 1 ATG14L 
PI3KC3 
p150 
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increase the interaction of ATG14L, PI3KC3 and Beclin 1 and this interaction was 
also confirmed through a yeast two-hybrid assay13. On the other hand, knockout 
of Dpr1, the mouse gene of Dapper 1, in mouse embryonic fibroblasts reduced 
the interaction of Atg14, Vps34, and Beclin 113. 
 
Complex II-UVRAG 
In Complex II, Beclin 1 interacts with UVRAG (mammalian homology to yeast 
Vps38) via interaction with the CCD. This interaction is thought to mediate the 
autophagy-independent functions of Beclin 1. Initially it was thought that UVRAG 
was important for autophagosome formation, but other groups have shown that 
UVRAG’s homologue did not function in the autophagic process in yeast. For 
example, loss of Atg14 in yeast results in decreased autophagosome formation 
which does not occur with loss of Vps3814. In fact, loss of Vps38 in yeast led to 
dysfunctional vacuolar protein sorting due to missorting of the Carboxypeptidase 
Y, a hydrolase that is known to be trafficked from the endosome to the vacuole in 
yeast15. This same finding was also confirmed in recent studies in Arabidopsis 
plant species as loss of Vps38 resulted in impaired vacuolar protein sorting but 
did not interrupt the autophagic process16.  In mammalian cells UVRAG mediates 
endosome-endosome and endosome-lysosome fusion via its interaction with 
Class C Vps complex, a major regulator of endosomal fusion17. These studies 
suggest that the Complex II interaction of UVRAG and Beclin 1 is important for 
mediating Beclin 1’s function in endosomal trafficking.  
	 6	
Functions of Beclin 1: Autophagy Dependent vs Autophagy Independent  
Autophagy-Dependent  
Beclin 1 is well known for its role in the initiation of macroautophagy, hereafter 
referred to as autophagy. Autophagy, which translates to “self eating” in Greek, is 
a conserved homeostatic process that cells use to recycle or degrade different 
cargos into macromolecules (carbohydrates, lipids, amino acids) that can be 
used for energy supply. Degradation of these cargos occurs via the lysosome. 
Cells utilize this process during times of nutrient stress or when macromolecules 
become limited to promote survival. Additionally, cells use autophagy during the 
immune response to get rid of intracellular pathogens18. The autophagic process 
can be selective or nonselective; nonselective autophagy usually involves the 
degradation of bulk cargos whereas selective autophagy usually involves the 
degradation of damaged protein and organelles. 
 
There are three well characterized types of autophagy: macroautophagy, 
microautophagy, and chaperone-mediated autophagy19-21. In microautophagy, 
the lysosomal membrane invaginates to capture cytosolic material which is then 
degraded19. In Chaperone-mediated autophagy, proteins are directly taken up 
into the lysosome via the LAMP-2A transmembrane protein that is located on the 
lysosome. A chaperone protein mediates this process (i.e. Heat Shock 70, 
Hsc70) as well as co-chaperones that recognize a specific sequence on 
substrates22. This targets cytosolic substrates to the lysosome for degradation 
	 7	
and they are translocated into the lysosome via LAMP2. During macroautophagy, 
an isolation membrane (or phagophore) captures some amount of cytoplasm. 
The isolation membrane elongates and eventually encloses to form an 
autophagosome, a double-layered membrane vesicle. This autophagosome can 
then fuse with a lysosome (i.e. autolysosome) to digest its contents including the 
inner membrane. Additionally, autophagosomes can fuse with other cellular 
components such as an endosome (known as an amphisome) before fusing with 
a lysosome. Macroautophagy is the most common type of autophagy and is 
regulated by Beclin 1. Therefore the machinery involved in this process will be 
described in greater detail in this thesis.  
 
Phases of Autophagy 
There are 3 main phases of autophagy that occur: Initiation/nucleation of the 
phagophore, expansion/elongation of the phagophore and autophagosome 
fusion/recycling/degradation of autophagosome contents (Figure 1.2).  
I. Initiation/nucleation of the phagophore:  
a. Autophagy is under tonic inhibition through the mechanistic target 
of rapamycin complex I (mTORCI). During the fed state, mTORC1 
is bound and phosphorylates a complex of Unc-51-like kinase 
family (ULK1 or ULK2), ATG13, and RB1-inducible coiled-coil 1 

























































































































































































































































































































mTORCI is no longer active and the ULK1/ATG13/RB1 complex is 
able to initiate the autophagic process26. 
b. Following induction, the Beclin 1-VPS34-ATG14L complex is 
recruited and nucleation of the isolation membrane or phagophore 
occurs3. Removal of tonic inhibition stimulus of mTORC1 results in 
ULK1 phosphorylation of Beclin 127. This results in Beclin 1 
activation of PI3KC3 to generate PI3P, which is necessary for 
phagophore formation. Many studies suggest that the mammalian 
isolation membranes arise from endoplasmic reticulum (ER) or 
other ER associated organelles28. 
II. Expansion/elongation of the phagophore:  
a. Elongation of the phagophore is mediated by two ubiquitin like 
(UBL) conjugation systems. The first system involves the 
multiprotein complex of ATG12, ATG5, and ATG16. In this 
conjugation system ATG7 (E1-like enzyme) and ATG10 (E2-like 
enzyme) conjugates ATG12 to ATG5 in an irreversible manner29. 
Following conjugation, the ATG12/ATG5 complex then binds to 
ATG16 to create a multiprotein complex30. In the second 
conjugation system, ATG8/LC3 is processed by cysteine protease 
ATG4 to generate LC3I31. LC3-I is then lipidated with 
phosphatidylethanolamine (PE) in a series of steps involving ATG7 
and ATG3 to generate LC3II30. This series of lipidation steps help to 
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elongate the phagophore and LC3II is found on both the inner and 
outer layer of the mature autophagosome.  
III. Autophagosome fusion and degradation/recycling of autophagosome 
contents: 
a. After expansion, the phagophore elongates and fuses to form an 
autophagosome (double membrane vesicle). The autophagosome 
can then be trafficked to a lysosome where its fuses and degrades 
its inner contents. The trafficking of the autophagosome to 
lysosomes is dependent on microtubules as microtubule disrupting 
agents have been shown to prevent fusion of autophagosome and 
lysosomes32. Additional studies suggest that SNARE proteins 
mediate fusion of autophagosomes with lysosomes33. Following 
fusion with lysosomes, autolysosome contents are digested and 
materials can be used as building blocks for cellular processes.  
 
Autophagy can be either tumor suppressive or tumor promoting. The process of 
autophagy can remove damaged organelles and protein aggregates that can 
cause elevated ROS, which can lead to genomic instability. Therefore, 
autophagy acts in a tumor suppressive manner by actively surveying for these 
damaged cargos. For example, immortalized mouse mammary epithelial cells 
that are heterozygous for beclin 1, showed impaired autophagy and increased 
genomic instability as evidenced by increase phosphorylation of DNA damage 
	 11	
protein γ-H2AX that indicates double stranded DNA breaks34. This increase in 
phosphorylation of γ-H2AX during metabolic stress was also observed in 
immortalized baby mouse kidneys that were heterozygous for beclin 135. 
Damaged or misfolded proteins are directed to the autophagosome through 
several autophagy receptors such as p62, a substrate for autophagy that binds 
protein aggregates. Increased susceptibility to metabolic stress was observed in 
autophagy defective immortalized baby mouse kidney epithelial cells (atg5 -/- or 
beclin 1+/-) as they exhibited accumulation of p62, damaged mitochondria, and 
increased endoplasmic reticulum chaperone proteins36. This stress was also 
associated with elevated ROS and chromosomal instability36. Additionally, p62 
overexpression resulted in increased tumorigenesis in autophagy defective cells 
and tumors exhibited increased ROS and DNA damage36. Taken together, these 
results indicate that autophagy can suppress ROS production to prevent DNA 
damage, genomic instability and tumorigenesis.  
 
Another line of evidence that autophagy can act in a tumor suppressive manner 
is the tumorigenesis exhibited by deletion of autophagy specific genes in mice. 
For example, systemic mosaic knockout of Atg5 in mice renders mice susceptible 
to liver adenomas, or benign liver growths37. This same phenotype is also 
observed in mice with liver-specific knockout of Atg737. Additionally, frameshift 
mutations in other autophagy genes such as ATG2B, ATG5, ATG9B and ATG12 
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are observed in human gastric and colorectal tumors with microsatellite 
instability38.  These results indicate a tumor suppressive role for autophagy.  
 
Interestingly, liver tumors observed in Atg5 systemic mosaic knockout or Atg7 
liver-specific knockout mice never progress to hepatocellular carcinoma 
suggesting that autophagy may be necessary for tumor progression37.  
Autophagy can also behave in a tumor-promoting manner. This is often observed 
in ischemic areas of tumors where there is increased nutrient stress. By 
activating autophagy, tumor cells can acquire macronutrients to promote survival 
in a stressful tumor microenvironment. For example, a study done by Eileen 
White showed that under ischemic conditions, a reduction of Beclin 1 and Atg5 
expression resulted in reduced viability of immortalized baby mouse kidney cells 
(iBMKs)39. Autophagy has also been shown to be tumor promoting in p53 
dependent tumors. In an in vivo model for pancreatic tumors, knockout of Atg7 or 
Atg5 prevented tumor progression and resulted in premalignant pancreatic 
lesions that did not progress to pancreatic ductal adenocarcinoma40. Other 
studies in pancreatic ductal adenocarcinoma show that pancreatic cancer cells 
are dependent on autophagy and are sensitive to autophagy inhibition by 
knockdown of autophagy genes or chemical modulation41. These studies suggest 
a role for autophagy that is tumor promoting as knockdown or knockout of 
autophagy genes prevent survival in ischemic conditions or prevents malignant 
tumor formation in genetic mouse models.  
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Autophagy-Independent Functions of Beclin 1 
While the majority of studies investigating Beclin 1 have focused on its role in 
autophagy, there is considerable evidence to support that Beclin 1 has essential 
autophagy-independent functions and it is likely that these functions impact the 
role of Beclin 1 as a tumor suppressor.  For example, homozygous deletion of 
Becn1 in mice results in embryonic lethality due to failed cavitation of the 
blastocyst42. In contrast, deletion of other essential autophagy genes such as 
Atg5 or Atg7 in mice results in healthy-appearing pups that succumb to death in 
the perinatal period (1 day following delivery)43,44. This difference in knockout 
phenotype supports that Beclin 1 has other essential autophagy-independent 
roles. An additional line of evidence that Beclin 1 has autophagy-independent 
functions is apparent when comparing tumor formation in heterozygous Becn1 
mice compared to mice deficient in Atg5 or Atg7. Becn1+/- mice develop 
spontaneous lung and liver adenocarcinomas, as well as lymphomas42,45. As 
stated previously, mice deficient in Atg5 or Atg7 do not develop malignant tumors 
but form benign hepatic adenomas (non-malignant liver growth)37. This difference 
in tumorigenesis between these essential autophagy genes provides support that 
the autophagy-independent functions of Beclin 1 contribute to the development 
and maintenance of malignant tumors.  
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Beclin 1 mediates its autophagy-independent functions through Complex II with 
the binding partner UVRAG. Reported functions include cytokinesis, 
endocytosis/endocytic receptor degradation, phagocytosis, and vacuolar protein 
sorting in yeast46. Complex II was shown to play a role in cytokinesis by the 
Stenmark group. Initially they discovered that PI3KC3 and Beclin 1 contributed to 
cytokinesis as loss of PI3KC3 and Beclin 1 resulted in a defective cytokinesis 
and resulted in cells that were multinucleated47. Complex II was implicated in 
cytokinesis in a follow up study that showed that knockdown of UVRAG but not 
ATG14L in HeLa cells resulted in impaired detachment of the midbody structure, 
which is present at the cleavage furrow48. Failure of the midbody to detach 
prevents the separation of two daughter cells during mitosis. This study 
implicated Complex II in the regulation of chromosomal number during mitosis 
and the prevention of aneuploidy, which can lead to genomic stress resulting in 
pathogenic processes such as cancer development.  
 
Multiple studies have implicated a role for Beclin 1 in endocytosis that is 
mediated through UVRAG/Complex II, as restoration of UVRAG but not ATG14L 
in Becn1 deficient mouse embryonic fibroblasts was able to rescue a deficiency 
in endosome formation and support neuronal development49. The role for Beclin 
1 in endocytosis is well conserved from lower to higher organisms. Beclin 1 
homologues in Drosophila Melanogaster as well as C. elegans have been shown 
to play a role in endocytosis. In Drosophila, Atg6 mutant animals show defects in 
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endocytosis as reduced uptake of Texas Red-avidin in larval fat bodies is 
observed50. Additionally, Atg6 mutant larval fat bodies have reduced Rab5 
perinuclear staining, a marker for early endosomes50. This change is not 
observed in Atg1 (ULK1/2 in mammalians) mutant flies. Another study in flies 
showed that loss of Atg6 results in an accumulation of early and late endosomes 
as well as endolysosomes51. This phenotype was phenocopied by UVRAG 
knockdown but not ATG14 knockdown, which again indicates that the role of 
Beclin 1 in endocytosis is mediated through Complex II and is independent of its 
functions in autophagy.  In C. elegans, a defect in endocytosis was observed by 
performing fluid uptake assays with Texas-Red in animals mutant in BEC-1 (C. 
elegans homologue to mammalian Beclin 1)52. Additionally, BEC-1 mutants 
showed defects in recycling MIG/Wntless protein from endosome to the Golgi. 
Instead it was trafficked to the lysosome for degradation52. These studies in lower 
organisms indicate a role for Beclin 1 in endocytosis and this role is mediated 
through its interaction in Complex II with UVRAG.  
 
A role for Beclin 1 in endocytosis has also been shown in mammalian systems as 
well. The Stenmark group showed that knockdown of Beclin 1, VPS34, and 
UVRAG in HeLa cells led to decreased degradation of the Epidermal Growth 
Factor Receptor (EGFR) through Rhodamine-EGF pulse chase and confocal 
microscopy assays48. Additionally, they determined that this function was specific 
to Complex II as knockdown of ATG14L did not alter EGFR degradation48. 
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However, other conflicting studies suggest that Beclin 1 does not regulate EGFR 
degradation53. The Maltese group showed that suppression of Beclin 1 in 
glioblastoma cells impaired autophagy but did not change EGFR degradation53. 
These studies suggest that the role of Beclin 1 in endocytosis could be cell type 
specific.  
 
Deregulation of both endocytic receptor degradation and cytokinesis can serve 
as a nidus for cancer development. As mentioned previously, UVRAG has been 
implicated for having a role in both endocytic receptor degradation and 
cytokinesis. Therefore, studies indicate that UVRAG has tumor suppressive 
behavior. In support of this, UVRAG is located in a tumor susceptible locus that is 
commonly mutated in multiple cancers such as colon, gastric, and breast. 
Microsatellite unstable colon carcinomas cells with monoallelic UVRAG 
mutations exhibit increased tumorigenic potential54. Frameshift mutations in 
UVRAG were identified in gastric tumors with microsatellite instability55. 
Additionally, UVRAG negatively regulates proliferation as colon cancer cells with 
monoallelic UVRAG mutations exhibit enhanced proliferation56. Loss of UVRAG 
promotes genomic instability independent of autophagy, as cells that lack 
UVRAG are prone to DNA damage in the form of double stranded DNA breaks57. 
Loss of UVRAG also gives rise to cellular aneuploidy due to destabilization of 
centrosomes57. Interestingly, UVRAG mutated cell lines do not exhibit impaired 
autophagy suggesting that the function of UVRAG in cancer is independent of 
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autophagy54,57. These studies all highlight the tumor suppressive activity of 
UVRAG, which mediates the autophagy-independent functions of Beclin 1 
through Complex II. Moreover, ATG14L, which is essential for the autophagic 
process through Complex, I, has not been shown to be mutated in cancer or to 
suppress tumorigenesis.   
 
Beclin 1 and Cancer 
Since its discovery, multiple functions for Beclin 1 have been identified including 
a role for Beclin 1 in cancer. Beclin is a haploinsufficient tumor suppressor as 
heterozygous loss of Becn1 in mice leads to spontaneous tumorigenesis. 
Becn1+/- mice develop lung and liver adenocarcinomas as well as multiple 
lymphomas when compared to control mice42,45. In addition, mammary glands 
from these mice show evidence of pre-malignant hyperplastic changes. 
Moreover, Becn1+/- mice exhibit enhanced mammary tumorigenesis following 
parity58. In humans, monoallelic loss of BECN1 is observed in 40% of breast, 
50% of prostate, and 75% of ovarian cancers59. Furthermore, overexpression of 
Beclin 1 in MCF7 cells in an orthotopic xenograft model prevents tumor formation 
and proliferation, further suggesting a tumor suppressive role for Beclin 1.  
 
The role of Beclin 1 as a tumor suppresser has been questioned due to the 
chromosomal positioning of BECN1. BECN1 is located on human chromosome 
17q21.  It is positioned next to BRCA1, a well know tumor suppressor gene that 
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regulates DNA repair and is commonly deleted in breast cancer. In one analysis 
of The Cancer Genome Atlas (TCGA) data it was determined that loss of BECN1 
occurred because of large deletions of the region in which BRCA1 was located60. 
These data suggested that BECN1 loss occurred because it was passenger 
gene that is lost when BRCA1 deletions occur. This co-deletion questions a role 
for Beclin 1 as a tumor suppressor. However other evidence to support Beclin 1 
as a tumor suppressor in multiple cancers has emerged. In a study of human 
breast tumors, low Beclin 1 expression was more commonly observed in ER 
negative (ER) breast tumors (HER2 and basal-like) than luminal tumor subtypes 
and reduced expression is associated with poor prognosis61. This same study 
found that reduced BRCA1 expression was not associated with basal like or 
HER2 enriched tumors and was not associated with patient prognosis61. This 
finding suggests that BECN1 is not a passenger deletion but may have important 
independent functions in cancer.  In human breast tumors, aberrant methylation 
of BECN1 decreases expression61. Beclin 1 expression is reduced in multiple 
TNBC cells lines59. In addition, low Beclin 1 expression is an independent 
predictor of patient prognosis in multiple cancers in addition to breast cancer, 
including oral tongue squamous cell carcinoma, gastric cancer and 
hypopharyngeal cancer62-64.  
 
While Beclin 1 expression is reduced in multiple cancers, this thesis will highlight 
breast cancer because a large majority of research on Beclin 1 and cancer has 
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focused on breast. The role of Beclin 1 in breast cancer has been studied in 
multiple genetic models of mammary tumor development in mice. Tumorigenesis 
was enhanced in mice with overexpressed WNT activation and heterozygous 
loss of BECN1 following parity. Additionally in an orthotopic xenograft model, 
overexpression of Beclin 1 in MCF7 breast cancer cells was shown to reduce 
tumor formation in mouse mammary glands of nude mice65. However, in a 
polyoma middle T oncogene driven tumor model and a HER2/ErBB2 
overexpressed tumor model, tumorigenesis was not enhanced in mice with 
heterozygous loss of BECN1. This suggests that the role of Beclin 1 in mammary 
tumorigenesis is context dependent and warrants further investigation to identify 
the molecular mechanism by Beclin 1 suppresses tumor formation58,66.  
 
Endocytic Pathway and Growth Factor Receptor Regulation 
Beclin 1 plays a role in endocytosis and reduced expression of Beclin 1 results in 
reduced degradation of some receptors (i.e. EGFR) that undergo endocytosis. 
Deregulation of growth factor receptor signaling can promote tumorigenesis. 
Therefore, insight into the function of Beclin 1 as a tumor suppressor can be 
gleaned by understanding the role of endocytosis in the regulation of growth 
factor receptor expression and function. Endocytosis is a process in which cells 
internalize membrane surface proteins or macromolecules that are targeted to 
different cellular compartments. Once internalized, cargos are sorted into 
intracellular vesicles called endosomes. Cargos that are packaged into 
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endosomes can have multiple fates ranging from recycling back to the plasma 
membrane or targeting to the lysosome for degradation. Deregulation of this 
intricate movement of internalized cargo has been implicated in multiple disease 
pathologies including neurodegenerative disorders, metabolic syndromes and 
cancer.  
 
There are multiple forms of endocytosis but the main two mechanisms by which 
endocytosis occur is through either Clathrin-mediated or caveolae-mediated 
endocytosis.  
I. Clathrin-mediated endocytosis (CME): Clathrin mediated endocytosis, 
also known as receptor-mediated endocytosis, is the most commonly 
studied form of endocytosis67. This mechanism involves the formation 
of clathrin coated pits as well as clathrin coated vesicles. Two of the 
most well studied receptors that are trafficked by CME are the low-
density lipoprotein (LDL) receptor and the Transferrin receptor (TFR1). 
The core machinery needed to facilitate CME includes clathrin, adaptor 
proteins and dynamin68. CME initiation occurs when adaptor protein 2 
(AP2) is recruited to lipid rich portions the plasma membrane69. 
Recruitment of AP2 allows for the assembly and recruitment of clathrin 
heavy and light chains creating the “pit”. This then allows for the 
docking of different cargo to the clathrin-coated pit. Clathrin coated 
vesicle formation is then mediated by dynamin, a GTPase which 
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recognizes BAR domain proteins that interact through Dynamin’s 
proline-rich domain70. Dynamin encircles clathrin coated invaginations 
to cause scission71. This creates the separation between the plasma 
membrane and the new clathrin coated vesicle. Clathrin is then 
removed from the vesicle through heat shock cognate 70 (Hsc70) and 
newly formed vesicles are trafficked to different cellular compartments.  
II. Caveolae-mediated endocytosis (CavME): Caveolae, the location of 
CavME, are flask or omega shaped invaginations that are present in 
most eukaryotic plasma membranes72,73. While not well understood, 
the main structure of caveolae consists of caveolin-1, caveolin-2 and 
caveolin-3, integral membrane proteins that insert into inner leaflets of 
the membrane bilayer and bind cholesterols to serve as a scaffold for 
different cargos72,74. Budding of caveolae is mediated by different 
kinases (src-family of kinases) and phosphatases75,76.  Similar to CME, 
dynamin triggers fission of caveolae to separate them from the plasma 
membrane77. Caveolae that are removed from the plasma membrane 
are then trafficked to different cellular localizations via the actin and 
microtubule cytoskeleton78.  
The endocytic pathway is made up of three main types of endosomes. The early 
endosome (EE) is responsible for receiving cargo from multiple endocytic entry 
points79. The late endosome (LE) targets endosomal contents to the lysosome or 
trans-golgi network79. The third component is the recycling endosome (RE), 
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which takes cargo from the EE population, and recycles this cargo back to the 
cell surface79. A small family of GTPases, a superfamily of enzymes that 
hydrolyze Guanosine Triphosphates (GTPs), known as Rab GTPases, regulate 
the endocytic process. Additionally, these Rab GTPases localize to different 
endosomal compartments (i.e. EE, LE, and RE). Over 60 Rab GTPases have 
been identified in the human genome and different Rabs localize to and are 
markers of specific endosomal compartments79. The early endosome is 
characterized as being Rab5 and Rab4 positive. Rab5 is one of the most 
commonly characterized Rab GTPases present on the early endosomal vesicle. 
Late endosome are characterized as Rab7 positive and recycling endosomes are 
Rab11 and Rab4 positive. Trafficking of cargos through these different 
endosomes (EE, LE, and RE) is crucial in the regulation of intracellular 
signaling79.  
 
Endocytic Regulation and Growth Factor Signaling 
The endocytic pathway can regulate the trafficking of multiple membrane proteins 
to different intracellular compartments. Additionally, the endocytic pathway can 
also regulate growth factor receptor signaling by recycling or degrading receptors 
thereby maintaining or inhibiting their signals, respectively. For example, multiple 
receptor tyrosine kinases (RTKs) are regulated by endocytosis. RTKs are 
transmembrane receptors for ligands such as growth factors, cytokines, and 
hormones that regulate multiple cellular processes. Upon ligand binding, a series 
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of tyrosine phosphorylation events leads to signal transduction triggering 
activation of downstream pathways. In order for the receptor to be recycled or 
degraded, RTKs undergo endocytosis through various endocytic compartments 
to be removed from the cell surface. Signaling through RTKs is tightly regulated 
through both space and time by intracellular trafficking components, and the 
process of endocytic internalization, degradation, and recycling of RTKs is 
fundamental for this regulation. Deregulation of these signaling pathways has 
been implicated in multiple disease pathologies including cancer initiation and 
progression. I will describe the regulation of RTKs by using the Epidermal Growth 
Factor receptor (EGFR) as an example because the endocytic regulation of 
EGFR has been studied most extensively.  
 
EGFR, also referred to as ErbB1/HER1, is one of the most commonly studied 
members of the EGFR family of RTKs that includes ErbB2/HER2/Neu, 
ErbB3/HER3, and ErbB4/HER4. Signaling through the EGFR leads to a multitude 
of functional downstream outcomes including cellular proliferation, differentiation, 
migration, growth and inhibition of apoptosis. The activation and downstream 
activity of the receptor is mediated by an extracellular ligand binding domain, 
transmembrane domain, kinase domain and the C-terminal tail domain.  
Following ligand binding, single EGFR monomers undergo dimerization and 
transphosphorylation of the C-terminal domain. Dimerization of the EGFR was 
first appreciated by Yarden and Schlessinger in the presence of the EGF 
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ligand80,81. Transphosphorylation of the EGFR allows for the phosphorylation of 
multiple tyrosine residues in the C-terminal tail domain. Following 
transphosphorylation, several proteins are recruited, such as GRB2 and SOS, 
which activate downstream RAS/RAF/MEK/ERK to promote cellular proliferation 
as well as PI3K to activate downstream AKT/mTOR signaling which promotes 
cell survival82. In addition to the RAS/RAF/MEK/ERK and AKT/mTOR pathways, 
dimerization of EGFR monomers can also activate other downstream signaling 
pathway axes such as PLCy1-PKC, JNK, and JAK-STAT. After activation of 
downstream signaling, EGFR signaling must be terminated. Activated EGFR is 
internalized through CME or CavME to attenuate signals83,84. Similar to other 
RTKs, once internalized, EGFR can be recycled back to the membrane or 
targeted to the lysosome for degradation.  
 
RTK Degradation and Recycling 
Activation of RTKs and subsequent degradation or recycling of receptors is 
regulated by the endocytic process. Internalized receptors can be ubiquitinated 
and this ubiquitination controls trafficking through the endosomal pathway. EGFR 
is internalized from the plasma membrane through CME and CIE pathways in an 
EGF ligand concentration dependent manner. Studies suggest that at low 
concentrations of EGF, CME was shown to be the route of internalization, 
however at high concentrations of EGF, CIE was determined to be the main 
mechanism of internalization85. However, a controversial study indicated that 
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EGFR internalization is impaired at both high and low concentrations of EGF in 
CIE86. EGFR is ubiquitinated by the Cbl family of ubiquitin ligases87. c-Cbl binds 
activated EGFR, which leads to mono-ubiquitination of the receptor88. Cbl along 
with the adaptor protein CIN85 were shown to interact with EGFR to mediate its 
endocytosis and degradation89. Ubiquitination of receptors allows for binding of 
other proteins that will change the fate of the receptor for either degradation or 
recycling. Similar to the EGFR, other RTKs such as the insulin-like growth factor 
receptor 1 (IGF-1R) are targeted for degradation through ubiquitination but this 
occurs through different adaptor proteins. Nedd4, an E3 ligase, mediates 
ubiquitination of the IGF-1R, which is internalized by both CME and CIE 
mechanisms90,91. Additional ubiquitin ligases have been shown to ubiquitinate 
IGF-1R to mediate endocytosis such as Mdm2 and c-Cbl92,93. 
 
Once internalized, key decision-making steps occur where RTKs are sorted into 
different endosomal compartments.  Such compartments include the recycling 
endosome (prolongs receptor signaling) or lysosome (attenuates receptor 
signaling). Ubiquitination is the key step in the degradation of RTKs as it tags 
proteins that are destined for lysosomal degradation.  Ubiquitinated cargos in 
endosomal membranes are detected by the endosomal-sorting complex required 
for transport (ESCRT) machinery (Figure 1.3)94. The ESCRT machinery, first 
discovered in yeast, is highly conserved in mammalian systems95. In yeast, 
depletion of the class E vacuolar sorting proteins (Vps) was found to cause  
Figure 1.3. Schematic of the ESCRT machinery. The ESCRT machinery is 
recruited to endosomal membranes by the FYVE domain of HRS binding to 
PI3P enriched at endosomes. This allows for other ESCRT-0 members to be 
recruited. The UIM domains of both HRS and STAM recognize and bind 
ubiquitinated cargos for sorting into intraluminal vesicles of the multivesicular 
body. ESCRT-I is recruited to the endosomal membrane by the interaction of 
the UEV domain of TSG101. ESCRT-II is then recruited by the interaction of 
Vps28 and the GLUE domain of EAP45. ESCRT-III is sequentially recruited by 
the interaction of EAP20 of ESCRT-II with CHMP6. ESCRT-III when activated 
encloses a ring around ubiquitinated cargos. The ESCRT machinery is 
removed by the ATPase Vps4 prior to sorting cargos to intraluminal vesicles. 
Adapted from Williams and Urbe94. 	
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defects in endosomal sorting as well as enlarged prevacuolar compartments that 
lacked internal vesicles96. These Vps proteins were found to assemble into multi-
subunit machinery consisting of ESCRT-0, I, II, and III. The ESCRT subunits are 
recruited to endosomal membranes in a sequential manner (i.e. 0 then I, II, and 
III) and facilitate trafficking of proteins to intraluminal vesicles (ILV), which go on 
to form the multivesicular body (MVB). The contents of the MVB get degraded 
upon fusion with the lysosome. The sequential recruitment of the ESCRT 
complexes to the endosome is termed the conveyor belt method97.  
 
ESCRT-0 consist of Hepatocyte Growth Factor-regulated Tyrosine Kinase 
Substrate HRS (mammalian orthologue to yeast Vps27) and Signal Transducing 
Adaptor Molecule STAM (mammalian orthologue to yeast Hse1) and initiates 
MVB formation by recognizing ubiquitinated cargo98,99. HRS is recruited to 
endosomes through binding of its Fab 1, YOTB, Vac 1, EEA1 (FYVE) zinc finger 
domain to PI3P and binds ubiquitinated proteins through its ubiquitin-binding 
motif (UIM)100-102. Following recruitment of ESCRT-0, ESCRT-I is recruited to 
endosomal membranes through HRS of ESCRT-0. ESCRT-I member TSG101 
binds HRS through its UEV domain103. ESCRT-I contains TSG101 (mammalian 
orthologue to yeast Vps23), Vps28, Vps37A-D, and ubiquitin associated protein 1 
(UBAP1). ESCRT-II is recruited to the endosomal membrane by Vps28 of 
ESCRT-I, which binds the GLUE domain of EAP45 (mammalian orthologue to 
yeast Vps36)104. ESCRT-II consists of EAP45 (mammalian orthologue to yeast 
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Vps36), EAP22 (mammalian orthologue to yeast Vps22) and two EAP20 
(mammalian orthologue to yeast Vps25). ESCRT-III is made up of 4 core 
subunits CHMP6, CHMP4(A-D) CHMP3, and CHMP2(A-B), (mammalian 
orthologue to yeast Vps20, Snf7, Vps24, Vps2 respectively). Multiple ESCRT-III 
complexes are recruited to the endosome by CHMP6 and once activated forms a 
ring structure around ubiquitinated cargos105. Vps4 is AAA+ ATPase is involved 
in the final steps of MVB biogenesis and helps to cycle ESCRT complexes off of 
endosomal membranes97,106. 
 
EGFR is targeted to the lysosome via the endosomal-sorting complex required 
for transport  (ESCRT) machinery. The ESCRT-0 proteins HRS and STAM, 
which initiate the targeting of this receptor to the lysosome, recognize 
ubiquitinated EGFR. Ubiquitination increases trafficking of the EGFR to the 
multivesicular body to enhance lysosomal degradation107. HRS and STAM are 
phosphorylated by EGFR at the endosomal membrane108. Recruitment of 
ESCRT-0 allows for the initiation of the degradative process of EGFR.  Although 
degradation of EGFR has been shown to occur through the lysosome, studies 
have also implicated a role for the proteasome in the degradation of EGFR. Cells 
treated with proteasome inhibitors exhibit delayed degradation of EGFR109. 
Similar to EGFR, studies suggest that IGF-1R is degraded at the proteasome as 
proteasome inhibitors reduce the degradation of the receptor110. This inhibition 
could be due to a decrease in ubiquitination which is needed for EGFR or IGF-1R 
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to be trafficked to the lysosome or because a portion of EGFR or IGF-1R is 
degraded at the proteasome.   
 
Although EGFR is degraded at lysosomes, another fate of the receptor is 
recycling to the cell surface. Studies show minimally ubiquitinated EGFR 
escapes degradation at the lysosome111. EGFR is trafficked to the recycling 
endosome through Rab35 or Rab11 via the perinuclear recycling compartment. 
The clathrin adaptor protein Eps15 was shown to mediate recycling of EGFR via 
Rab11 to traffic back to the membrane112.  
 
Intracellular Signaling Through Endosomes  
RTKs were originally thought to only transmit signals from the plasma 
membrane. However, this idea was challenged when subcellular fractionation 
identified downstream signaling proteins that are activated downstream of RTKs 
in endosomes. In rats injected with EGF prior to euthanization, fractionation 
experiments in liver tissues found that downstream adaptor proteins such as 
GRB2 and SHC localized with EGFR in large endosomes113. These same 
findings were identified following activation of the insulin receptor, another RTK, 
as activated MAPK accumulated in endosomes when detected by magnetic 
microbeads114. These experiments highlighted endosomes as potential platforms 




The functional relevance of endosomal signaling was identified in studies 
examining signaling in neurons. Nerve Growth Factor (NGF), which activates the 
TrkA receptor, propagates signals through endosomes down long neuronal 
axons and disruption of this signaling allowed for sustained signaling 
downstream of the TrkA receptor115,116. The actual transport of endosomes was 
visualized in axons by live imaging using quantum dot labeled NGF; transport of 
NGF was found to be unidirectional117. These results established a role for 
receptor trafficking of signaling downstream of the plasma membrane and 
identified a role for endosomes as signaling-competent compartments in the 
cytoplasm. These findings suggested that these signaling-competent endosomes 
regulate signaling in different subcellular locations upon ligand activation of 
receptors.  
 
The ability of RTKs to propagate signals through endosomes has been shown in 
other studies. EGFR is associated with multiple of its downstream effectors in 
different endosomal compartments using endosomal isolation and 
immunofluorescence techniques118. In one study, the Wiley group used a 
reversible biotinylated EGFR antibody to isolate EGFR and associated proteins 
in different subcellular compartments and generated phospho-specific EGFR 
antibodies to examine activity of the receptor118. Using the biotinlyated antibody 
and fluorescence techniques, they determined that EGFR remains active in 
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endosomes and associated with different adaptor proteins118. A more recent 
study using FRET microscopy determined that EGFR remains phosphorylated 
and active in endosomes and can recruit adaptor protein Shc1119. These studies 
indicate further that signaling can be propagated in endosomes.  
 
Signaling from endosomes and silencing of signals is tightly linked. The ESCRT 
machinery, which binds ubiquitinated cargos destined for degradation, is required 
for the generation of intraluminal vesicles. The generation of intraluminal vesicles 
that merge to create MVBs removes active receptors from a signaling competent 
compartment to a signaling-incompetent compartment, thus attenuating signals. 
Deregulation of receptor trafficking can lead to increased signaling in signaling 
competent compartments and this aberrant signaling can promote disease 
pathogenesis. This delay may help to explain why many cancers, including 
breast, have elevated activity of RTKs. 
 
Alternative subcellular mechanisms to regulate signaling: 
While the endosomal pathway is one way to regulate receptor signaling, other 
mechanisms for controlling signaling exists. For example, the cellular 
cytoskeleton is an important regulator of growth factor receptor signaling 
downstream of multiple RTKs. The cytoskeleton has the ability to regulate 
receptors and aid in their activation. The cytoskeleton can impact receptor 
signaling, dimerization, and endosomal trafficking. The actin cytoskeleton can 
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also work with the microtubule axis to drive movement of different endosomal 
vesicles (EE, LE, and RE), which aid in the movement of receptors or different 
cargos to multiple subcellular sites120. This can also influence receptor signaling. 
For example, the RTK and proto-oncogene c-Met was shown to have sustained 
signaling in perinuclear endosomes through activation of Rac-1, a Rho GTPase 
family member. Rac-1 is known to initiate actin cytoskeleton changes that 
promote cellular migration121,122. In this study they were able to show that Rac-1 
dependent changes in the cytoskeleton promoted enhanced signaling from active 
c-Met in perinuclear endosomes123. Another example of RTK signal regulation by 
the cytoskeleton was shown through the neurofibromatosis type 2 (NF2) tumor 
suppressor Merlin. Merlin interacts with alpha-catenin, an actin binding protein, 
and can localize to the cortical cytoskeleton124. Merlin regulates EGFR signaling 
by immobilizing EGFR to the plasma membrane and preventing its 
internalization125. Additionally loss of Merlin was shown to enhance recycling of 
the EGFR126. These studies indicate an important role for cytoskeletal regulation 
of growth factor receptors.  
 
Another factor that can influence RTK signaling is plasma membrane lipid 
compositions. Lipid rafts, or area of the plasma membrane that are high in 
cholesterols and sphingolipids can either negatively or positively regulate RTK 
signaling. For example, EGF stimulation in methyl-β-cyclodextrin (cholesterol 
inhibitor) treated NIH 3T3 cell, leads to increase activation of MAPK downstream 
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of EGFR127,128. Analysis of other RTK signaling pathways such as the Insulin 
receptor (IR) or Platelet derived growth factor receptor (PDGFR) reveal that 
depletion of lipid raft cholesterol impairs downstream signaling129,130. The results 
of these studies indicate the importance of cholesterol and lipids to RTK function 
and signaling. It also highlights a receptor dependent role for lipids as loss of 
cholesterol can either promote or inhibit signaling.  
  
Beclin 1 Regulation of Growth Factor Receptor Signaling 
As previously mentioned, Beclin 1 has been implicated in having a role in the 
endocytic process that has been conserved from lower organisms to complex 
mammalians. Beclin 1 regulates vacuolar protein sorting in yeast. Atg6 mutant 
Drosophila show defects in endocytosis as well has reduced Rab 5 expression in 
their larval fat bodies50. Additionally, C. elegans with mutant BEC-1 have reduced 
endocytosis of Texas-Red marker uptake and defects in the recycling and 
trafficking of the MIG/Wntless protein52. In a mammalian system, knockdown of 
Beclin 1 leads to reduced degradation of the EGFR through confocal 
microscopy48. Together, this literature suggests a role for Beclin 1 in regulating 
endocytosis.  
 
Given that multiple receptors and their signaling are regulated at the level of 
endocytosis, it begs the questions of whether or not Beclin 1 can regulate growth 
factor receptor signaling through its regulation of endocytosis? Several studies 
	 34	
provide evidence that Beclin 1 can regulate growth factor signaling at the level of 
the endosome. In lower organisms such as Drosophila, depletion of Atg6 
increases Notch in early endosomes as well as enhanced Notch signaling from 
endosomes51. This enhanced Notch signaling was detected by a EGFP 
reporter51. In a mammalian system using mouse embryonic fibroblast (MEFs), 
knockdown of Beclin 1 resulted in reduced degradation of EGFR following EGF 
stimulation49. 
 
Previous work from our lab identified a novel role for Beclin 1 in regulating growth 
factor receptor signaling in multiple breast cancer subtypes. Knockdown of Beclin 
1 resulted in enhanced and sustained signaling activity following EGF or IGF1 
stimulation. We identified that loss of Beclin 1 results in delayed endosomal 
maturation as evidenced by retained APPL+ endosomes131. APPL is an adaptor 
protein that is present on early endosomes in the absence of PI3P132. Following 
accumulation of PI3P at endosomal membranes, APPL is displaced by FYVE 
domain carrying proteins to continue the endosomal maturation process132. 
shBECN1 cells stimulated with EGF or IGF1 exhibited increased APPL+ 
endosomes suggesting a delay in maturation131. Additionally, analysis of human 
tumors showed an inverse correlation of Beclin 1 expression with AKT or MAPK 
expression. Taken together, these data suggest a role of Beclin 1 in the 
regulation of growth factor receptor signaling. Given that this work was performed 
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in vitro, it is important to understand whether Beclin 1 can regulate growth factor 
receptor signaling in vivo.  
 
Rationale for Thesis Project 
 
Multiple studies have implicated Beclin 1 in having a role in cancer progression. 
This role for Beclin 1 in cancer has been attributed almost exclusively to its role 
in autophagy. However multiple studies provide evidence for autophagy-
independent functions of Beclin 1 that can impact cancer progression. Although 
Beclin 1 regulates processes that are important for all types of cancer, the 
majority of studies have been performed in breast cancer. Low Beclin 1 
expression is associated with poor prognosis in multiple aggressive breast 
cancer subtypes. However, the exact mechanism by which loss of Beclin 1 
promotes breast cancer progression has yet to be elucidated.  Previous work 
from our lab identified a role for Beclin 1 in the endocytic regulation of growth 
factor receptor trafficking and signaling in vitro in a breast cancer model. 
However, a deeper understanding of the role of Beclin 1 in cancer is necessary in 
order to identify and develop novel treatment approaches for patients with 
aggressive disease. Therefore, for my thesis project, I sought to understand the 
mechanism by which Beclin 1 contributes to breast cancer tumor growth and 
progression in vivo. Given that Beclin 1 is able to regulate growth factor receptor 
signaling by modulating endocytic trafficking in vitro, it was important to assess 
whether this function affects tumor growth and progression in vivo. It was also 
important to assess whether Beclin 1 has roles in cancer progression that are 
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outside of its known role in autophagy. By understanding Beclin 1 function in 
vivo, it could potentially shed light on alternative avenues for treatment of 
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Beclin 1 has non-autophagic functions that include its ability to regulate endocytic 
receptor trafficking.  However, the contribution of this function to tumor 
suppression is poorly understood.  Here, we provide in vivo evidence that Beclin 
1 suppresses tumor proliferation in an autophagy-independent manner by 
regulating the endocytic trafficking and degradation of the epidermal growth 
factor (EGFR) and transferrin (TFR1) receptors.  We discovered that Beclin 1 
promotes endosomal recruitment of hepatocyte growth factor tyrosine kinase 
substrate (HRS), which is necessary for sorting surface receptors to intraluminal 
vesicles for signal silencing and lysosomal degradation.   In tumors with low 
Beclin 1 expression, endosomal HRS recruitment is diminished and receptor 
function is sustained.  Collectively, our results demonstrate a novel role for Beclin 
1 in impeding tumor growth by coordinating the regulation of key growth factor 
and nutrient receptors. These data provide an explanation for how low levels of 
Beclin 1 facilitate tumor proliferation and contribute to poor cancer outcomes, 








Beclin 1 is a haploinsufficient tumor suppressor that is is associated with poor 
prognosis in a number of cancer types42,133.  In breast cancer, reduced Beclin 1 
expression is an independent predictor of poor overall patient survival134. 
Heterozygous loss of Beclin 1 (BECN1+/-) promotes mammary tumorigenesis in 
response to parity and enhances WNT1-driven mammary tumor progression135. 
The majority of studies that have investigated Beclin 1 function in cancer have 
focused on its role in regulating macroautophagy (hereafter referred to as 
autophagy). Autophagy is a conserved homeostatic and stress response 
pathway by which damaged proteins and organelles are engulfed within a double 
membrane vesicle and degraded upon fusion with lysosomes to prevent 
cytotoxicity and recycle macromolecules for energy supply136,137.  While a role for 
autophagy in suppressing tumor initiation has been supported by experimental 
studies138, a paradoxical requirement for autophagy function in tumor progression 
has also been revealed139,140.  For example, knockout of Atg5, an essential 
autophagy gene that is required for the elongation and closure of the 
autophagosome, enhances tumor initiation in a Kras mouse model of pancreatic 
cancer, but these tumors remain benign and do not progress to invasive 
cancer41.  Moreover, Kras/p53-driven lung tumors revert to benign oncocytomas 
upon acute knockout of Atg7, another essential autophagy gene important for 
autophagosome elongation141.  These outcomes contrast with the enhanced 
tumor growth and progression observed in mice when Beclin 1 expression is 
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reduced42,133,135.  The requirement of autophagy for the development and 
maintenance of malignant tumors conflicts with the role of Beclin 1 as a tumor 
suppressor, and this discrepancy underscores the likelihood that alternative 
functions of Beclin 1 are involved in its regulation of tumor progression. 
 
Autophagy-independent functions of Beclin 1 have been less studied in the 
context of cancer, although growing evidence supports their involvement in tumor 
suppression.  Beclin 1 (Atg6/Vps30) regulates membrane trafficking events 
through its interaction with p150 (Vps15) and the lipid kinase class III 
phosphatidylinositol-3 kinase (PI3KC3/Vps34)142,143. This Beclin 1 core complex 
interacts in a mutually exclusive manner with either ATG14L/BARKOR (Atg14; 
Complex I) or UVRAG (Vps38; Complex II) to regulate distinct vesicular 
trafficking functions144,145. Complex I regulates autophagy and Complex II 
regulates autophagy-independent functions including vacuolar protein sorting, 
cytokinesis, phagocytosis, fluid phase endocytosis and endolysosomal receptor 
trafficking144,146,147.  Beclin 1, UVRAG and another Complex II-specific binding 
partner BIF-1 each suppress xenograft tumor growth when overexpressed, a 
finding not reported for ATG14L56,148,149.  This selective regulation supports a 
unique role for Beclin 1 and Complex II in cancer.   
 
One mechanism by which Beclin 1 may regulate tumor growth and progression is 
through the control of endolysosomal trafficking, which plays an important role in 
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controlling the outcomes of cell surface receptor function150,151. For growth factor 
receptors, ligand binding initiates internalization and entry into the early 
endosome compartment, which is required for the activation of some signaling 
pathways152. Other receptors, such as the transferrin receptor (TFR1), are 
internalized constitutively in a ligand-independent manner153. Once internalized 
into early endosomes, receptors are sorted to either late 
endosomes/multivesicular endosomes (MVEs) where they are sequestered 
within intraluminal vesicles (ILVs) for signal termination and subsequent 
degradation upon fusion with the lysosome154,155, or to the recycling endosomes 
for return to the cell surface156.  Beclin 1, UVRAG and BIF-1 have been reported 
to regulate the rate at which the epidermal growth factor receptor (EGFR) is 
degraded after stimulation with its ligand EGF146,157.  In previous work, we 
showed that Beclin 1 regulates phosphatidylinositol-3 phosphate (PI3P) 
production in response to growth factor stimulation and promotes the transition of 
PI3P-negative (PI3P-) early endosomes to PI3P+ endosomes158,159.  By doing so, 
Beclin 1 controls the length of time that growth factor receptors remain in the 
PI3P- signaling competent compartment and consequently determines the 
duration of growth regulatory signals159.  The fact that Beclin 1 expression 
inversely correlates with AKT and ERK phosphorylation in human breast tumors 
is indicative that this Beclin 1-dependent regulation of growth factor receptor 
signaling occurs in human cancer159.   
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Despite knowledge that Beclin 1 has been implicated in growth factor receptor 
signaling and trafficking, much remains to be learned about the mechanism by 
which this occurs.  PI3P is necessary for the recruitment of FYVE (Fab1p, YOTB, 
Vac1p, EEA1) or PX (Phox homology) domain containing effector proteins that 
control the trafficking fate of cargo within the endocytic pathway. However, 
specific PI3P-interacting proteins that are regulated by Beclin 1 have not been 
identified.  Moreover, the existing data on Beclin 1 regulation of trafficking were 
derived from in vitro studies and the impact of Beclin 1 on receptor trafficking and 
signaling in vivo, and the effect on tumor behavior, has not been demonstrated. 
In the current study, we identify an autophagy-independent mechanism by which 
Beclin 1 regulates the trafficking and function of growth factor and nutrient 
receptors that drive tumor cell proliferation in vivo. These findings provide novel 
insight into the mechanism by which Beclin 1 regulates receptor function and 
how loss of Beclin 1 expression contributes to tumor progression.   
 
MATERIALS AND METHODS  
 
Cells, antibodies and reagents.  MDA-MB-231 LM2 4175 human breast cancer 
cells were purchased from the laboratory of Joan Massague (Memorial Sloan 
Kettering Cancer Center, Cornel University) and grown in DMEM media 
containing 10% FBS 160.  Authenticated SUM-159 cells were a kind gift from Art 
Mercurio (UMass Medical School, Worcester, MA) and grown in F12 Hams 
media supplemented with 5% FBS, 500mM HEPES, 1.5mg Insulin and 1mg/mL 
hydrocortisone. Expanded stocks were frozen down and fresh knockdown cells 
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were generated after two months in culture.  Cells tested negative for 
mycoplasma using the Morwell MD Biosciences EZ PCR Mycoplasma Test Kit 
(cat# 409010).  Stable knockdown cell lines were generated using lentiviral 
vectors containing shRNAs that target human BECN1 (TRCN0000033550, 
TRCN0000033552), ATG5 (TRCN0000151963, TRCN0000151474) and TFRC 
(TRCN0000057660) (Open Biosystems, Lafayette, CO, USA).  pLKO.1 
puromycin containing shRNA that targets green fluorescent protein (GFP) was 
purchased through Addgene (Cat# 30323).  For dual expression, shRNAs were 
sub-cloned into a pLKO.1 neomycin vector (Addgene; cat # 13425) using EcoRI 
and MfeI sites.  For restoration of Beclin 1 expression, FLAG-Beclin 1 with silent 
mutations that disrupt shRNA targeting was subcloned into the pCDH-puro 
lentiviral vector 159.  Stable cell lines were selected with 2ug/ml of puromycin 
(Gold Bio), 0.5ug/ml G418 Neomycin (Gold Bio), or both.   
 
Antibodies recognizing Beclin 1 (cat# 3738), ATG5 (cat# 2630), p44/42 MAPK 
(ERK1/2; cat#9102), pT202/Y204-MAPK (pERK1/2; cat# 4370), EGFR (cat# 
4267), pY1068-EGFR (cat# 3777), HRS (cat# 15087), AKT (cat# 9272), pT308-
AKT(cat# 4056) and phospho-Histone H3 (cat# 9701), as well as mouse IgG1 
(cat# 5415) and normal rabbit IgG (cat# 2729) were purchased from Cell 
Signaling Technologies (CST) (Danvers, MA). Transferrin receptor (cat# 13-
6800) and actin (cat# MA5-11869) antibodies were purchased from Invitrogen 
(Carlsbad, CA).   LC3B (cat# L7543), Tubulin (cat# T5168) and pY334-HRS (cat# 
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SAB4504231) were purchased from Sigma (St. Louis, MO).  Ki67 antibodies 
were purchased from Abcam (Cambridge, UK; cat# 66155).   
 
Autophagic flux assays.  Cells were plated in 24 well tissue culture dishes 
overnight and then incubated with complete DMEM containing 100nM 
Rapamycin (Sigma; cat# R0395), 40nM Bafilomycin (Sigma; cat# B1793), or both 
for 8 hours.  Cells were extracted in radioimmune precipitation assay (RIPA) lysis 
buffer (25 mm Tris (pH 8.0), 0.1% sodium dodecyl sulfate, 1% sodium 
deoxycholate, 1% Nonidet P-40, 150 mm sodium chloride, 10 mm sodium 
fluoride, and 1 mm sodium orthovanadate) containing complete mini protease 
inhibitors (Roche). Cell extracts containing equivalent amounts of total protein 
were analyzed for LC3I to LC3II conversion by immunoblotting.  
 
Orthotopic in vivo assays.  LM2 cells were trypsinized, washed five times with 
PBS and cells (1 x 106) were resuspended in 35 µL Matrigel (10mg/ml; Trevigen, 
Gaithersburg, MD; cat#3432-005-01) immediately prior to injection into the 3rd 
mammary fat pad of NOD/SCID mice.  Tumors were measured twice weekly with 
calipers for 5-8 weeks. Tumor volume was calculated using the following 
equation: 4/3π[(LxHxW)/2]. Tumors were excised and portions were either snap 
frozen for immunoblotting and mRNA analysis, fixed in 10% buffered formalin for 
immunohistochemistry or placed in culture medium for ex vivo analysis.  
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Ex vivo tumor analysis.  Following tumor dissection, equal size tumor slices 
were equilibrated in DMEM containing 10% fetal bovine serum and 
supplemented with penicillin/streptomycin for 24 hours in a 5% CO2 incubator.  
To assess pathway involvement in proliferation, tumor slices were incubated with 
DMSO (Sigma; cat# D5879), 5uM Lapatinib (Selleckchem; cat# S1028) or 10uM 
PD98059 (Selleckchem; cat# S1177) for 48 hours. Tissues were either flash 
frozen for protein extraction and analysis by immunoblotting or fixed in 10% 
buffered formalin and paraffin-embedded for IHC analysis.   
 
Reverse Phase Protein Array. Frozen pieces of three tumors of each genotype 
(shGFP, shBECN1, and shBECN1:Beclin 1) were sent to the MD Anderson 
Cancer Center Reverse Phase Protein Array (RPPA) Core Facility.  RPPA was 
performed according to their previously published protocol using the standard 
antibody list updated 3.  
 
Immunoprecipitation and Immunoblotting.  Cells were serum starved for 1 hr 
in serum-free medium and then stimulated with human recombinant EGF (Sigma; 
cat#9944) for the time periods indicated in the Figure Legends prior to extraction.  
Cells were solubilized at 4oC in a 20 mM Tris buffer, pH 7.4 containing 1% 
Nonidet P-40, 0.137 M NaCl, 10% glycerol, 10 mM sodium fluoride, 1 mM 
sodium orthovanadate and protease inhibitors (Roche).  Frozen tumors were 
extracted at 4°C in Tissue Protein Extraction Buffer (Thermo Scientific; cat# 
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78510) containing 1mM sodium orthovanadate, 10mM NaF and protease 
inhibitors (Complete Mini Tab; Roche, Indianapolis, IN, USA).  For 
immunoprecipitations, aliquots of cell or tumor extracts containing equivalent 
amounts of protein were pre-cleared for 1 hr with non-specific IgG and protein-A 
or -G sepharose beads (GE Healthcare) and then incubated for 3 hrs with 
specific antibodies and protein-A or -G sepharose beads with constant agitation.  
The beads were washed three times in extraction buffer and laemmli sample 
buffer was added to the samples.   
 
Whole cell or tumor extracts containing equivalent amounts of protein or immune 
complexes were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes, and immunoblotted as described previously 161,162. Bands were 
detected by chemiluminescence using a ChemiDoc XRS+ system (Bio-Rad 
Laboratories,Hercules, CA, USA) and band intensities were quantified by 
densitometry using Image Lab (Beta 1; Bio-Rad Laboratories) or Image J.  Only 
signals within a linear range were used for quantitation and signals were 
normalized to total protein and/or housekeeping genes.    
 
Immunofluorescent staining.  Subconfluent, adherent cells plated on glass 
coverslips were serum starved for 2 hrs and then treated with or without EGF-
Alexafluor 555 for 10 minutes.  Cells were washed three times with cold 
Dulbecco’s PBS and fixed in 3.8% paraformaldehyde in Dulbecco’s PBS with 
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0.5% Tween (PBST) for 1 hr.  Permeabilized cells were blocked for 1 hr using 
3% BSA in PBST.  Primary antibodies diluted in blocking buffer were added to 
cells and incubated at room temperature for 1 hr.  Secondary antibodes were 
diluted in the same buffer and cells were incubated at room temperature for an 
additional 30 minutes.  Cells were washed three times with PBST after each 
antibody incubation. Coverslips were then mounted on glass slides using Prolong 
Gold containing DAPI (Cell signaling) and the slides were viewed by confocal 
microscopy (Ziess LSM700; 63X oil immersion objective).  All images were 
adjusted equally for brightness/contrast using Adobe Photoshop. 
 
Immunohistochemistry. Formalin-fixed, paraffin-embedded tissue sections 
(5uM) were deparaffinized and rehydrated, and antigen retrieval was performed 
in 10mM sodium citrate buffer, pH 6.0 with heating in a steamer for 1hr.  Tissues 
were incubated with 0.3% Hydrogen peroxide to quench endogenous peroxides 
and then blocked using a dual avidin/biotin blocking kit (Vector Laboratories; cat 
# SP-2001) followed by a 1-hour incubation in 1x casein milk (Vector 
Laboratories; cat# SP-2050). Tissue sections were incubated with primary 
antibodies overnight followed by secondary antibody incubation with the elite 
ABC-HRP kit (Vector Laboratories; cat# PK6101). Sections were developed with 
diaminobenzidine (DAB) (Dako; cat# K3468) and then counterstained with 
hematoxylin.  Stained tumor sections were viewed on an Olympus BX41 light 
microscope (Olympus). Images were captured with an Evolution MPColor 
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camera (Media Cybernetics).  All images were adjusted equally for brightness 
and contrast using Adobe Photoshop. 
 
Cell death was analyzed by TUNEL staining according to manufacturer’s 
instructions (Promega, cat# G3250). Stained tissue sections were viewed and 
images captured on a Zeiss LSM-700 microscope. All images were adjusted 
equally for brightness and contrast using Adobe Photoshop.   
 
Quantitative Polymerase Chain Reaction (qPCR).  RNA was extracted from 
tumors using the RNA-easy kit (Qiagen; cat# 74134).  cDNA was synthesized 
using a one-step cDNA kit (Biotool; cat# B22403).  RT-qPCR was performed in a 
20 uL reaction containing 0.5 uM primers, 20 ng cDNA template, and 1x SYBR 
green supermix (biotool; cat# B2120).  Primers were designed using the Harvard 
PrimerBank (Table 1).  Human R18S primers were used as a housekeeping 
control. RT-qPCR was performed using the Applied Biosystems QuantStudio 6 
Flex apparatus.  The delta –delta Ct method was used to determine relative 
mRNA expression.  
 
Statistical Analysis.  Statistical analysis between two groups was performed 
using the two-tailed unpaired student’s t-test.  Statistical analysis was performed 
using Prism7, Graphpad.  A two-sided p-value of <0.05 was considered to 
indicate statistical significance.  K means clustering was performed in MATLAB 
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using the built-in function ‘kmeans’ using the distance metric squared Euclidean.  




Beclin 1 regulates endosomal HRS recruitment  
Our previous in vitro studies demonstrated that Beclin 1 regulates Insulin-like 
growth factor-1 (IGF-1R) and EGFR receptor trafficking and signaling by 
controlling the activation of VPS34 and generation of PI3P159.  Ligand-dependent 
receptor activation stimulates the production of PI3P and this increase is inhibited 
when Beclin 1 expression is suppressed159.  Reduced PI3P levels result in 
delayed receptor degradation, but the mechanism of this regulation is not known.  
A primary signal for sorting receptors that are destined for lysosomal degradation 
is receptor ubiquitination163,164. Ubiquitinated receptors are recognized by the 
hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), which 
contains both an ubiquitin binding (UIM) domain and a FYVE domain165-167. The 
HRS FYVE domain recognizes PI3P in the early endosomal membrane and is 
required for its recruitment to these vesicles168,169.  In cells treated with 
wortmannin to reduce PI3P levels and inhibit HRS recruitment to the early 
endosome, activated receptors escape sorting into intraluminal vesicles (ILVs) of 
multivesicular endosomes (MVE), a step prior to lysosomal degradation, and 
their signaling and expression are prolonged170,171. 
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We hypothesized that suppression of Beclin 1 sustains growth factor receptor 
expression and signaling because HRS recruitment to the early endosome is 
limited, allowing receptors to escape sorting to the ILVs and delay degradation.  
To investigate this potential mechanism of Beclin 1 function, we used a variant of 
MDA-MB-231 cells (hereafter referred to as LM2 cells) because Beclin 1 
expression is elevated in these cells when compared across a panel of TNBC 
cells172.  Cells were generated that stably express shRNA targeting either GFP 
(control) or BECN1.  This approach was taken to mimic the reduction, but not 
complete loss, of Beclin 1 expression that is commonly observed in human 
tumors134,173.  Beclin 1 expression was restored in the shBECN1 cells using a 
construct in which silent mutations were introduced into the region of BECN1 
targeted by the shRNA to control for specificity of the knockdown159.  To visualize 
the recruitment of HRS to endosomes, cells were treated with EGF-AlexaFluor 
555 (EGF-555) to stimulate and monitor trafficking of the EGFR and co-stained 
with HRS-specific antibodies (Figure 2.1).  HRS localization was primarily diffuse 
in the cytoplasm of serum-starved cells, with a few puncta evident.  After 
stimulation for 10 min, a similar number of EGF-555 positive puncta were 
detected in shGFP, shBECN1 and shBECN1:Beclin 1 cells, supporting an 
equivalent level of EGFR activation. The number of cytoplasmic HRS puncta 
increased markedly in shGFP cells after stimulation, and these puncta co-
localized with EGF-555. Significantly fewer HRS puncta were induced by EGF 
stimulation in shBECN1 cells, but rescue of Beclin 1 expression restored HRS 
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Figure 2.1. shBECN1 cells exhibit reduced colocalization of EGF and 
HRS Puncta. MDA-MB-231 LM2 cells expressing shGFP, shBECN1 or 
shBECN1:Beclin 1 were serum starved and then stimulated with EGF-
AlexaFluor 555 (200ng/ml) for 10 minutes.  Cells were co-stained with HRS-
specific Abs. Scale bar = 10uM. The data shown in the graph represent the 
number of HRS and EGF puncta per cell. shGFP n=25, shBECN1 n=20 





puncta formation. These results support that the EGF-stimulated recruitment of 
HRS to endosomes is regulated in a Beclin 1-dependent manner. 
 
To investigate the Beclin 1-dependent regulation of HRS further, we evaluated 
the tyrosine phosphorylation of HRS in response to EGF stimulation.  HRS is 
phosphorylated in response to EGFR activation and this phosphorylation event 
requires PI3P-mediated recruitment of HRS to endosomes, making it a surrogate 
marker for HRS endosome localization165,171,174. Cell extracts from EGF-
stimulated LM2 cells were immunoprecipitated with HRS-specific antibodies and 
immunoblotted with phosphotyrosine-specific antibodies to evaluate total HRS 
phosphorylation levels.  EGF-stimulated HRS phosphorylation was decreased in 
cells expressing shRNA targeting two different sites within BECN1 when 
compared with shGFP cells (Figure 2.2A).  HRS phosphorylation was also 
reduced when Beclin 1 expression was suppressed in another TNBC cell line 
SUM-159PT (Figure 2.2B).  A similar pattern of phosphorylation in shGFP and 
shBECN1 cells was detected in immunoblots of whole cell extracts using a 
phospho-specific HRS antibody (pY334-HRS), and the reduced HRS 
phosphorylation in shBECN1 cells was increased upon rescue of Beclin 1 
expression (Figure 2.2C).   In contrast, no difference in EGF-stimulated HRS 
phosphorylation was detected between shGFP cells and LM2 cells expressing 
two independent shRNA targeting ATG5 (Figure 2.2D), supporting an autophagy-
independent mechanism for this HRS regulation by Beclin 1.   
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Figure 2.2. Beclin 1 regulates receptor trafficking through HRS. (A) 
MDA-MB-231 LM2 cells expressing shGFP, shBECN1 (#1) or shBECN1 (#2) 
were stimulated with human EGF (50ng/ml) for the indicated time periods. 
Total cell extracts were immunoprecipitated with HRS-specific antibodies and 
immunoblotted with antibodies specific for phosphotyrosine (pTyr).  The blot 
was stripped and re-probed with HRS-specific antibodies.  Total cell extracts 
were also immunoblotted with the indicated antibodies. (B) SUM-159 cells 
expressing shGFP, shBECN1 (#1) or shBECN1 (#2) were stimulated with 
human EGF (50ng/ml) for the indicated time periods. Total cell extracts were 
immunoprecipitated with HRS-specific antibodies and immunoblotted with 
antibodies specific for phosphotyrosine (pTyr).  The blot was stripped and re-
probed with HRS-specific antibodies.  Total cell extracts were also 
immunoblotted with the indicated antibodies. (C and D) MDA-MB-231 LM2 
cells expressing shGFP, shBECN1 or shBECN1:Beclin 1 (C) or shGFP, 
shATG5 (#1) or shATG5 (#2) (D) were stimulated with human EGF (50ng/ml) 
for the indicated time periods. Total cell extracts were immunoblotted with the 
indicated antibodies.  
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Beclin 1 regulates tumor proliferation in an autophagy-independent 
manner. 
To investigate whether Beclin 1/HRS-dependent regulation of receptor trafficking 
impacts tumor growth, Beclin 1 knockdown and rescue cells were injected into 
the mammary fat pad (mfp) of NOD/SCID mice.  shBECN1 cells expressing 
reduced Beclin 1 grew at an increased rate, and the final tumor volume was 
significantly greater when compared with shGFP control tumors (Figure 2.3A).  
Rescue of Beclin 1 expression (shBECN1:Beclin 1) significantly diminished tumor 
growth rate and size (Figure 2.3A), confirming the specificity of the Beclin 1 
knockdown.  To explore the autophagy-dependent and independent functions of 
Beclin 1, LM2 cells expressing shRNA targeting ATG5 were also evaluated for 
tumor growth.  In contrast to the enhanced tumor growth observed upon 
suppression of Beclin 1 expression, the growth rate and final tumor volume of 
shGFP and shATG5 tumors was similar (Figure 2.3C).   
 
To determine the extent to which autophagy was inhibited by Beclin 1 or ATG5 
suppression, autophagic flux was examined by treating cells with either 
rapamycin to inhibit mTOR and stimulate autophagy, bafilomycin A1 to inhibit 
lysosomal degradation, or both together175.  A similar reduction in LC3-I to LC3-II 
conversion was evident in the shBECN1 and shATG5 cells (Figure 2.4A), 
demonstrating that inhibition of autophagy was similar in these cells.  Moreover, 
autophagic flux was restored to control shGFP levels in the shBECN1:Beclin 1 
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rescue cells (Figure 2.4B). Importantly, the reduction in autophagy observed in 
vitro was maintained in vivo as the processing of LC3-I to LC3-II was decreased 
for both shBECN1 and shATG5 tumors when compared with shGFP and 
shBECN1:Beclin 1 tumors (Figure 2.3B and 2.3D).    
 
Tumor sections were analyzed for either Phospho-Histone H3 (PH3) or TUNEL 
staining to determine if the enhanced growth observed for shBECN1 tumors 
resulted from increased proliferation or decreased cell death, respectively.  
shBECN1 tumors exhibited increased PH3 staining compared to shGFP and 
shBECN1:Beclin 1 tumors (Figure 2.5A).  In contrast, no differences in TUNEL 
staining were detected (Figure 2.5C).  Both PH3 and TUNEL staining were 
equivalent in the shGFP and shATG5 tumors, reflecting their similar growth rates 
(Figures 2.5B and 2.5D).  Taken together, our results support the conclusion that 
the enhanced tumor growth observed for shBECN1 tumors does not result from 
decreased autophagy alone and that alternative functions of Beclin 1 are 
involved in its regulation of tumor cell proliferation.  
 
Regulation of EGFR and ERK1/2 signaling by Beclin 1 controls tumor 
proliferation 
To explore further the hypothesis that Beclin 1 regulates tumor proliferation 
through the control of endocytic receptor trafficking, we performed an unbiased 
high-throughput, quantitative reverse phase protein array (RPPA) to assess the  
Figure 2.3. Comparison of tumor growth in autophagy deficient cell 
lines. (A) Tumor growth of orthotopic xenografts in NOD-SCID mice.  Inset, 
Beclin 1 expression prior to injection.  (B) Expression of Beclin 1 and LC3II/I 
in tumors.  The data shown in the graph on the right represent the mean +/-
SEM expression of seven tumors.  (C)  Tumor growth of orthotopic xenografts 
in NOD-SCID mice.  Inset, ATG5 expression prior to injection.  (D) Expression 
of ATG5 and LC3II/I in tumors.  The data shown in the graph on the right 
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Figure 2.4. Comparison of autophagic flux in autophagy deficient or 
competent cell lines. (A-B) MDA-MB-231 LM2 cells expressing shGFP, 
shATG5, shBECN1 or shBECN1 with restored Beclin 1 expression 
(shBECN1:Beclin 1) were assayed for autophagic flux.  Cells were incubated 
for 8 hours in complete serum alone or with 100nM Rapamycin (Rap), 40nM 
Bafilomycin A1 (Baf) or Rapamycin and Bafilomycin A1 combined (Rap + 
Baf).  The data shown in the graphs on the right represent the mean +/-SEM 
LC3II/LC3I ratio of three independent experiments. *, p<0.05 relative to 
shGFP; #, p<0.05 relative to shBECN1 
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Figure 2.5. Comparison of proliferation and TUNEL staining in tumors. 
(A-B) Representative images of Phospho-histone H3 (PH3) staining in 
shGFP, shBECN1, shBECN1:Beclin 1 and shATG5 tumors.  The data shown 
in the graphs represent the mean +/-SEM positive nuclei/high powered field 
(hpf; five independent images/five tumors; n = 25).  Scale bar = 50uM. (C-D) 
Representative images of TUNEL staining in shGFP, shBECN1, 
shBECN1:Beclin 1 and shATG5 tumors. The data shown in the graphs 
represent the mean +/-SEM positive nuclei/hpf (three independent images/six 
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expression of 302 proteins and phosphoproteins that have important functions in 
cancer176,177.  This array included many growth factor receptors and downstream 
signaling effectors that have been implicated in tumor proliferation. Tumor lysates 
from three tumors of each genotype (shGFP, shBECN1 and shBECN1:Beclin 1) 
were analyzed by RPPA. Unsupervised hierarchical clustering of the Z-scored 
data revealed segregation of the shBECN1 tumors from the shGFP and 
shBECN1:Beclin 1 tumors, with the exception of one shGFP tumor that co-
segregated with the shBECN1 tumors (Figure 2.6).   K means clustering was 
used as an unbiased approach to identify changes in expression patterns that 
are unique to shBECN1 tumors.  Based on an analysis of the root-mean-square 
error (RMSE) we selected 18 clusters (K=18) as having the optimal balance 
between the similarity of the signaling profiles within each cluster while 
maintaining a small overall number of clusters (Figure 2.7A). Of the 18 distinct 
expression patterns that were identified, sub-clusters 1 and 11 contained proteins 
and phosphoproteins that exhibited increased expression in shBECN1 tumors 
when compared with shGFP and shBECN1:Beclin 1 tumors (Figure 2.7B). 
 
Analysis of sub-clusters 1 and 11 identified several growth factor (GF) and 
hormone receptors (EGFR, IRβ, c-KIT, VEGFR2, phosphoHER3) and their 
downstream signaling intermediates (pY759-phospholipase C gamma2 (PLCg2), 
pS664-protein kinase C delta (PKCd), and pS116-PEA-15) that were increased 
in shBECN1 tumors (Figures 2.8A and 2.8D).  In addition, pT202/Y204-
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extracellular regulated kinases 1/2 (pERK1/2), major regulators of cell cycle 
progression, as well as ERK1/2 substrates (pS383-ELK1 and pS318/S321-
FOXO3A) were also increased in shBECN1 tumors (Figures 2.8B and 2.8D).  
Analysis of all mitogen activated protein kinase (MAPK) pathway components 
(receptors, kinases and downstream substrates) that were included in the RPPA 
analysis revealed a significant enrichment for MAPK pathway activity in sub-
cluster 1 and elevated pathway activity in sub-cluster 11 (Figure 2.8C).  In 
contrast, increased PI3K/AKT pathway activity was not evident in the shBECN1 
tumors by RPPA analysis, indicating a selective activation of the MAPK signaling 
pathway in these tumors.   
 
Immunoblot analysis of additional tumors (n=7) confirmed increased EGFR 
expression and activation of ERK1/2 in shBECN1 tumors when compared with 
shGFP and shBECN1:Beclin 1 tumors (Figures 2.9A and 2.9B).  This analysis 
also suggested that EGFR is preferentially localized within a signaling competent 
compartment in shBECN1 tumors. Specifically, relative EGFR activation, as 
measured by phosphorylation of Y1068-EGFR, a GRB2 binding site, was similar 
across all tumors, but downstream ERK1/2 phosphorylation was significantly 
increased (Figures 2.9A and 2.9B).  pS473-AKT levels were not elevated in the 
shBECN1 tumors, confirming the RPPA findings that PI3K/AKT signaling is not 
enriched in the shBECN1 tumors.  Increased EGFR expression and pERK1/2 
activity and equivalent AKT activity were also validated in a second cohort of 
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shGFP and shBECN1 tumors (Figures 2.10A, 2.10B and 2.10D).  In contrast, 
EGFR expression and ERK1/2 activity were not elevated in shATG5 tumors 
(Figures 2.11A and 2.11B), providing further evidence that the regulation of this 
signaling pathway by Beclin 1 occurs independently of its regulation of 
autophagy. 
 
EGFR mRNA levels were not significantly different across the three tumor 
genotypes indicating that Beclin 1 regulates EGFR at the level of protein 
expression (Figure 2.9C).   To examine the hypothesis that this regulation occurs 
through EGFR endolysosomal trafficking, HRS tyrosine phosphorylation was 
assessed in the tumors.  Overall HRS phosphorylation was lower in the tumors 
than detected after acute EGF stimulation in vitro.  However, reduced HRS 
phosphorylation was detected in the shBECN1 tumors when compared with 
shBECN1:Beclin 1 tumors (Figure 2.9D).  These results support our conclusion 
that Beclin 1 regulates HRS function in vivo to control receptor trafficking.   
 
To assess the functional contribution of the EGFR/ERK signaling pathway to the 
enhanced proliferation observed in shBECN1 tumors, shGFP and shBECN1 
tumor slices were incubated ex vivo for 48 hrs in the presence of either the 
EGFR/HER2 dual inhibitor Lapatinib or PD98059, an inhibitor of MEK, the 
upstream regulator of ERK1/2 activation178-180. Tumor morphology was 






















































































































































































































































1    2   3    4   5    6    7   8    9 
Figure 2.6 Hierarchical Clustering 
of Reverse Phase Protein Array 
( R P PA ) d a t a . U n s u p e r v i s e d 
hierarchical clustering of the Z-scored 
RPPA data. . 
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7-9: shBECN1:Beclin 1 
A 
Figure 2.7. RPPA analysis clades of K=18. (A) Root-mean-square error 
(RMSE) graph from K means clustering analysis. (B) K means clustering 
analysis of RPPA data from three shGFP (1-3), shBECN1 (4-6) and 
shBECN1:Beclin 1 (7-9) tumors.  Log2 data was converted to Z-scores to 
perform K-means clustering analysis.  Images represent consensus plots for 
K=18 (18 sub-clusters).  Red boxes identify sub-clusters with elevated 
expression patterns in shBECN1 tumors.. 
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Figure 2.8. RPPA analysis identifies enhanced ERK1/2 signaling 
pathway activity in shBECN1 tumors. (A-B) Scatter-plots of sub-cluster 1 
(A) and sub-cluster 11 (B) highlighting growth factor/hormone receptors and 
ERK1/2 signaling pathway activity. (C) Enrichment analysis for a MAPK 
signaling signature. Orange, odds ratio; Blue, p-value.  Dotted line represents 
–log10(1.3) which indicates a p value of 0.05. (D) List of proteins/ 




































































Figure 2.9. Validation of enhanced EGFR/ERK1/2 signaling pathway 
activity in shBECN1 tumors. (A) Immunoblot analysis of representative 
shGFP, shBECN1 and shBECN1:Beclin 1 tumors.  (B) The data shown in the 
graphs represent the mean +/-SEM expression of seven tumors from each 
genotype and are shown as fold change in expression relative to shGFP 
tumors.  (C) Relative mRNA expression was determined by real-time 
quantitative PCR (RQ-PCR).  The data shown represent the mean +/-SEM 
mRNA expression of five (shGFP and shBECN1:Beclin) or four (shBECN1) 
tumors. p<0.05. (D) Tumor extracts from representative shGFP, shBECN1 
and shBECN1:Beclin 1 tumors were immunoprecipitated with HRS-specific 
antibodies and immunoblotted with antibodies specific for phosphotyrosine 
(pTyr).  The blot was stripped and re-probed with HRS-specific antibodies.  
Lanes from the same immunoblot were merged as indicated by the black line.  
The data shown in the graph represent the mean +/- SEM HRS 
phosphorylation of four tumors of each genotype and are shown as relative 
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Figure 2.10. Validation of additional orthotopic xenograft tumor study. 
(A) Tumor growth of shGFP and shBECN1 LM2 orthotopic xenografts in 
NOD-SCID mice.  Inset, Beclin 1 expression prior to injection. (B) Immunoblot 
analysis of shGFP and shBECN1 tumors. (C-D) Graphs showing the mean 
+/-SEM expression of six tumors from each genotype.  Data are shown as 
fold change in expression relative to shGFP tumors. p<0.05; ***, p<0.005 
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Figure 2.11. shATG5 tumors do not exhibit enhanced EGFR/ERK1/2 
signaling pathway activity. (A) Immunoblot analysis of representative 
shGFP and shATG5 tumors. (B) The data shown in the graphs represent the 
mean +/-SEM expression of six tumors from each genotype and are shown 























staining in tumors that were immediately fixed (untreated) or incubated ex vivo 
(DMSO) (Figure 2.13).   
 
Pathway activity in the ex vivo tissue slices and inhibition of activity by the drugs 
were confirmed by immunoblotting tumor extracts (Fig 2.12A). EGFR activity 
(pY1068-EGFR) was inhibited significantly by Lapatinib in both shGFP and 
shBECN1 tumors.  MEK activity, as measured by pT202/Y204-ERK1/2 levels, 
was also inhibited significantly in both tumor genotypes by PD98059, but pEGFR 
levels remained the same in the presence of this drug.  ERK1/2 phosphorylation 
was not inhibited in response to Lapatinib treatment, which may reflect the fact 
that these tumors express constitutively active mutant Ras that acts downstream 
of the EGFR and sustains ERK1/2 activation in the presence of this drug181.  
ERK1/2 function is regulated at both the level of activation (phosphorylation) and 
localization, with transition from the cytoplasm to the nucleus required for growth 
factor-dependent cell cycle entry 182.  Therefore, we assessed the localization of 
ERK1/2 in tumor sections treated with Lapatinib (Figure 2.12B).  Homogeneous 
staining was evident in the DMSO treated tumors, indicating that ERK1/2 was 
present in both the cytoplasm and nucleus.  In contrast, treatment with Lapatinib 
resulted in a decrease in nuclear staining (white arrows), indicating that ERK1/2 
function was inhibited by this drug treatment.    
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The ex vivo tumor sections were analyzed for Ki67 expression by IHC staining to 
assess proliferation (Figure 2.13). shBECN1 tumors exhibited increased Ki67 
staining when compared with shGFP tumors, indicating that the enhanced 
proliferation observed in vivo was maintained during the ex vivo incubation 
period.  Ki67 expression was reduced significantly in the shBECN1 tumors in 
response to both Lapatinib and PD98059 treatment.  Although a similar trend 
was observed for shGFP tumors, the decrease in Ki67 staining was not 
significant for either drug, suggesting that the enhanced EGFR/ERK signaling 
that occurs in shBECN1 tumors renders their proliferation more dependent upon 
this signaling pathway and more sensitive to inhibition by these drugs.     
     
Beclin 1 regulates Transferrin Receptor-1 (TFR1) expression to drive tumor 
proliferation 
Additional analysis of our RPPA data revealed that TFR1 expression was 
significantly upregulated in shBECN1 tumors (Figure 2.14A).  The ability of cells 
to proliferate requires not only a growth factor stimulus but also the appropriate 
metabolic conditions to support the anabolic processes that must occur for a cell 
to divide183.  Iron is an essential nutrient cofactor for enzymes that are involved in 
DNA synthesis and cell cycle and it is required for proliferation184,185.  
Extracellular iron is bound by transferrin and transported into cells by endocytic 
trafficking of TFR1153.  TFR1 expression correlates with proliferative capacity and 
receptor levels are elevated in tumor cells to satisfy the increased iron demand of  
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Figure 2.12. Inhibition of EGFR and ERK1/2 signaling in tumors. (A) 
Immunoblot analysis of representative shGFP and shBECN1 tumors treated 
ex vivo for 48 hrs with DMSO, Lapatinib (Lap; 5uM), or PD98059 (PD; 10uM).  
The data shown in the graphs represent the mean +/-SEM expression of 
eight tumors of each genotype.  (B) Immunofluorescent staining for ERK1/2 
expression in representative ex vivo tumors treated with DMSO or Lapitinib.  
Arrows indicate representative cells with reduced nuclear localization of 













DMSO Lapatinib PD98059 DMSO Untreated 
Figure 2.13. Proliferation in shBECN1 tumors is sensitive to inhibition of 
EGFR and ERK1/2 signaling. Representative images of H&E or Ki67 
staining of shGFP and shBECN1 tumors treated ex vivo as indicated. The 
data shown in the graph below represent the mean +/-SEM positive nuclei/
hpf (three independent images/five tumors; n = 15). Scale bar = 50uM. *, 
p<0.05; ***, p<0.005 
71	
	 72	
these rapidly dividing cells184,186.  Increased expression of TFR1 in shBECN1 
tumors and restoration of expression to shGFP levels in shBECN1:Beclin 1 
tumors was confirmed by immunoblotting (n=13 tumors) (Figures 2.14B and 
2.14C).  Similar to EGFR mRNA expression, TFRC mRNA levels were equivalent 
across the tumor genotypes (Figure 2.14D), indicating that increased TFR1 
expression in shBECN1 tumors also occurs at the level of protein expression. 
TFR1 protein expression did not increase in shATG5 tumors, supporting that the 
upregulation of TFR1 expression in shBECN1 tumors occurs in an autophagy-
independent manner (Figure 2.14E).  
 
The link between Beclin 1 and TFR1 was unexpected because TFR1 is typically 
sorted in the early endosome for constitutive recycling back to the cell surface.  
As a result of this recycling, expression remains constant.   However, TFR1 can 
be ubiquitinated by members of the membrane associated RING-CH (MARCH) 
family of ubiquitin ligases and this ubiquitination targets TFR1 for lysosomal 
degradation187,188.  We hypothesized that TFR1 is ubiquitinated in the tumor 
microenvironment and TFR1 levels increase in tumors with low Beclin 1 
expression because these ubiquitinated receptors escape HRS-mediated sorting 
to the lysosome for degradation.  In support of this mechanism of regulation by 
Beclin 1, elevated TFR1 expression was associated with increased ubiquitination 
in shBECN1 tumors (Figure 2.14F).  
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To determine if increased TFR1 expression contributes to the enhanced 
proliferation of shBECN1 tumors, LM2 cells were co-infected with shRNA 
targeting BECN1 and TFRC.  Cells with a modest suppression of TFR1 
expression, resulting in expression levels equivalent to the levels observed in 
shGFP cells, were selected for further in vivo analysis.  Restoration of TFR1 
expression to control shGFP tumor levels inhibited the enhanced tumor growth 
observed in cells expressing shBECN1 alone (Figure 2.15A and 2.15B).  Tumor 
sections were analyzed for PH3 or TUNEL staining to determine if the reduced 
growth observed upon suppression of TFR1 expression in the shBECN1 tumors 
was the result of decreased proliferation or increased cell death, respectively 
(Figures 2.15C and 2.15D).  As we observed previously (Figure 2.5A and 2.5C), 
shBECN1 tumors exhibited increased PH3 staining compared to shGFP tumors 
and no differences in TUNEL staining were detected.  shBECN1:shTFRC tumors 
exhibited PH3 and TUNEL staining equivalent to shGFP tumors, indicating that 
Beclin 1-dependent control of TFR1 expression contributes to tumor cell 
proliferation.   
 
We infer from our receptor trafficking and in vivo data that low HRS expression in 
human tumors should be associated with poor patient outcomes.  To assess the 
significance of HRS expression in human breast cancer, the impact of HRS 
expression on patient outcomes was analyzed using Kaplan-Meier plotter189.  
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Figure 2.14. TFR1 expression is elevated in shBECN1 tumors. (A) 
Scatter-plot of sub-cluster 1 from the K means clustering analysis of RPPA 
data highlighting TFR1 expression in the triplicate tumors of each genotype. 
(B) Expression of TFR1 in shGFP, shBECN1 or shBECN1:Beclin 1 tumors. 
(C) The data shown in the graph represent the mean +/-SEM TFR1 
expression from thirteen tumors of each genotype and are shown as fold 
change in expression relative to shGFP tumors. (D) TFRC mRNA expression 
in shGFP, shBECN1, or shBECN1:Beclin 1 tumors. The data shown 
represent the mean +/- SEM TFRC expression from five tumors of each 
genotype. (E) Expression of TFR1 in shGFP and shATG5 tumors. The data 
shown in the graph represent the mean +/-SEM TFR1 expression from six 
tumors of each genotype and are shown as fold change in expression relative 
to shGFP tumor. (F) Tumor extracts from representative shGFP and 
shBECN1 tumors were immunoprecipitated with TFR1-specific antibodies 
and immunoblotted with antibodies specific for Ubiquitin (Ub). The blot was 
stripped and re-probed with TFR1-specific antibodies.  Lanes from the same 
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Figure 2.15. Reduction of TFR1 expression in shBECN1 tumors 
suppresses tumor proliferation. (A) MDA-MB-231 LM2 cells expressing 
shGFP, shBECN1 or shBECN1:shTFRC were assayed for  tumor growth as 
orthotopic xenografts in NOD-SCID mice.  (B) Expression of Beclin 1 and 
TFR1 in tumors.  The data shown in the graph below represent the mean +/-
SEM expression from six tumors of each genotype. (C) Representative 
images of PH3 staining in shGFP, shBECN1 and shBECN1:shTFRC tumors. 
The data shown in the graph represent the mean +/-SEM positive nuclei/hpf 
(five independent images/five tumors; n = 25).  Scale bar = 50uM. (D) 
Representative images of TUNEL staining in shGFP, shBECN1 and 
shBECN1:shTFRC tumors. The data shown in the graph represent the mean 
+/-SEM positive nuclei/hpf (three independent images/six tumors; n = 18).  
Scale bar = 50uM. *, p<0.05; ***, p<0.005 
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(RFS) when all breast cancer subtypes were analyzed together, and this 
significance was maintained upon analysis of only Basal subtype tumors (Figure 
2.16A).  By contrast, HRS expression did not correlate with RFS in HER2 
positive tumors.  
 
This lack of significant correlation likely reflects the fact that HER2 is not 
downregulated by HRS-dependent sorting to the lysosome and therefore the 
expression and activity of these receptors would not be enhanced if HRS 
expression was reduced190,191.  The inverse association of HRS with RFS 
supports that the control of receptor trafficking is important for the suppression of 
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Figure 2.16. Mechanism for Beclin 1 regulation of receptor trafficking 
through HRS.  (A) Kaplan Meier plots showing the impact of HRS 
expression on the relapse free survival (RFS) of human breast tumors.  (B) 
Model of Beclin 1-dependent regulation of receptor trafficking.  In cells 
expressing Beclin 1, ubiquitinated EGFR and TFR1 are targeted for 
degradation by HRS-dependent sorting to ILVs and fusion with the lysosome. 
In cells with reduced Beclin 1 expression, ubiquitinated receptors escape 
sorting to the ILVs and lysosome because PI3P levels are reduced and HRS 
recruitment recruited to the early endosomes is inhibited.  As a result, EGFR 





We demonstrate that Beclin 1 regulates endocytic receptor trafficking by an 
autophagy-independent mechanism and conclude that this function of Beclin 1 
contributes to its role as a tumor suppressor. Specifically, we show that Beclin 1 
regulates the endosomal recruitment of HRS, which is essential in the sorting of 
receptors for signal silencing and degradation.  When Beclin 1 expression is 
reduced in tumors, early endosome recruitment of HRS is diminished and 
expression and activation of receptors that would normally be sorted for 
degradation persists (Figure 2.16B).  A consequence of this prolonged 
expression and function is increased tumor proliferation.  By RPPA analysis, we 
identified two independent growth regulatory receptors that contribute to 
enhanced proliferation when Beclin 1 expression levels are decreased.  EGFR 
expression and function are elevated and downstream ERK1/2 activation is 
increased, and this enhanced activity renders tumor proliferation more sensitive 
to drugs that target this signaling pathway.  Expression of the iron transporter 
TFR1 is also increased in tumors when Beclin 1 expression is low and this 
nutrient receptor supports enhanced tumor cell proliferation.  Taken together, our 
data reveal an autophagy-independent mechanism by which Beclin 1 regulates 
receptor trafficking and provide insight into how reduced Beclin 1 expression in 
tumors contributes to progression.  
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Our demonstration that Beclin 1 controls the early endosome recruitment of HRS 
to impact receptor sorting identifies a novel mechanism by which the expression 
and functional outcomes of cell surface receptors can be regulated.  This 
regulation can be mediated through either changes in Beclin 1 expression, which 
occurs in tumors and is modeled in our current studies, or function, such as 
through post-translational modifications of Beclin 1 that disrupt its interactions 
with PIK3C3.  For example, phosphorylation of Beclin 1 by EGFR or AKT inhibits 
its interaction with PI3KC3, resulting in decreased lipid kinase activity192,193.  
Ubiquitination of Beclin 1 also reduces PI3KC3 activation by targeting Beclin 1 for 
proteasomal degradation194. These modifications of Beclin 1 inhibit PI3P 
production, which prevents HRS recruitment and delays receptor sorting to the 
lysosome.  Beclin 1 post-translational modifications likely regulate the duration of 
receptor signaling and expression in normal cells in response to physiological 
stimuli, and may further alter receptor trafficking when these pathways are 
activated in tumors.  Our data demonstrate an important role for Beclin 1/HRS 
regulation of EGFR trafficking in TNBC.  However, many additional growth 
regulatory receptors are regulated by endolysosomal trafficking and would be 
impacted by Beclin 1 expression195-199.  As one example, in Drosophila, Atg6 (the 
Drosophila homolog of Beclin 1) regulates Notch and Wingless signaling 
pathways through the control of lysosomal receptor degradation200.  In Atg6 
mutant flies, receptor signaling is sustained which results in cell polarity and 
developmental defects.  Future studies are warranted to determine if the 
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expression and activity of other receptors that are downregulated by 
endolysosomal trafficking are enhanced in tumors upon reduction of Beclin 1 
expression and if this mechanism of regulation contributes to their oncogenic 
properties.   
 
Although Beclin 1 has been implicated as a tumor suppressor, the mechanisms 
involved have not been well characterized42,133.  Our conclusion that Beclin 1 
controls the endocytic trafficking of growth factor and nutrient receptors that drive 
tumor proliferation provides novel insight into this problem. Importantly, this 
mechanism of action may explain conflicting reports on the role of Beclin 1 as a 
tumor suppressor.  We discovered that the expression and function of the EGFR 
and downstream activation of ERK1/2 increased in shBECN1 tumors and that 
this enhanced signaling promoted tumor proliferation.  This result is consistent 
with the fact that TNBC is frequently associated with elevated EGFR expression 
and activity201.  However, we posit that the functional impact of Beclin 1 loss in an 
individual tumor will likely reflect the level of addiction to a specific receptor 
signaling pathway and whether it is controlled by HRS and endocytic trafficking.  
For example, heterozygous Beclin 1 loss enhances tumor development and 
growth in a mouse mammary tumor model driven by WNT-1, which acts through 
Frizzled receptors135.  EGFR, TFR1 and the Frizzled receptors are cell surface 
receptors whose expression and function are regulated by endolysosomal 
trafficking153,202,203. In contrast, mammary tumorigenesis and growth are not 
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enhanced by heterozygous loss of Beclin 1 in mouse models driven by either the 
polyoma-middle T oncogene (PyMT) or HER2204.  PYMT is a cytoplasmic protein 
that regulates activation of PI3K, MAPK and Src signaling pathways 
independently of upstream receptor regulation205.  Therefore, disruption of HRS-
mediated endocytic sorting would not be anticipated to enhance signaling and 
promote tumor growth in this model.  Although HER2 is a surface receptor that is 
internalized into the endocytic pathway, it is not targeted for degradation but 
instead is preferentially sorted to the recycling endosome190.  In fact, 
heterodimerization of HER2 with EGFR inhibits EGFR degradation and promotes 
recycling to the cell surface191.  Therefore, disruption of the signals that promote 
receptor sorting to the endolysosomal pathway would not be expected to 
enhance HER2 expression or function, and tumor growth would not be promoted 
by loss of Beclin 1 expression. In this regard, HRS expression is not predictive of 
outcomes in HER2 positive tumors.   
 
Our implication of Beclin 1 in the regulation of TFR1 expression is novel and 
significant for understanding how Beclin 1 affects tumor proliferation.  Iron is an 
essential nutrient for cell growth and proliferation and enhanced iron metabolism 
is commonly observed in tumors to support their rapid proliferation184,206.  In 
breast cancer, iron levels are increased when compared with normal breast 
tissue and an iron-regulatory gene signature is prognostic for patient outcome207.  
As TFR1 is the major source of iron uptake into cells, regulating its expression is 
	 82	
key to maintaining iron homeostasis.  TFR1 expression can be regulated in an 
iron-dependent manner at the level of mRNA stability through the binding of iron-
responsive proteins-1 (IRP-1) and IRP-2) to elements in the 3’ untranslated 
region208,209.  However, TFR1 protein expression can also be regulated through 
ubiquitination and sorting to the lysosome for degradation, a mechanism that 
allows for the acute regulation of metabolically available iron, or the labile iron 
pool188,210,211.  Our finding that Beclin 1 regulates TFR1 expression at the level of 
protein expression and that increased TFR1 ubiquitination is observed in 
shBECN1 tumors can be explained by decreased HRS endosomal recruitment 
that allows ubiquitinated TFR1 to escape sorting to the lysosome.  Collectively 
our results provide a novel mechanism by which Beclin 1 coordinates the 
regulation of both growth factor (EGFR) and nutrient receptors (TFR1) that are 
important for cell proliferation, and demonstrate how coordinated dysregulation of 
these pathways upon loss of Beclin 1 expression drives tumor proliferation.  
 
Our study provides insight into opportunities for the clinical management of 
tumors with low Beclin 1 expression.  We observed that shBECN1 tumors were 
more sensitive to inhibition of proliferation by EGFR and MEK inhibitors than 
control tumors, indicating a greater dependence of these tumors on the 
enhanced EGFR/ERK signaling that occurs when Beclin 1 expression is reduced.  
Although EGFR expression is frequently upregulated in TNBC, clinical trials of 
EGFR inhibitors in these patients have not shown overall efficacy212.  Screening 
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of patients with low Beclin 1 expression could identify subgroups of patients that 
would be more sensitive to these drugs, as well as inhibitors of other receptors 
that are regulated by trafficking, to improve outcomes.  TFR1 is also of clinical 
interest both as a drug target and because of its potential for drug delivery184.  
Tumors expressing elevated levels of TFR1, such as we observed in shBECN1 
tumors, would be more sensitive to the inhibition of iron-uptake by antibodies that 
block TFR1 function or iron chelators213,214.  In addition, transferrin-
chemotherapeutic drug conjugates that are transported intracellularly by 
endocytosis of the TFR1 would be more effective in tumors that express low 
levels of Beclin 1 and elevated TFR1215.  Tumors with reduced Beclin 1 
expression are also anticipated to be more sensitive to drugs that stimulate 
ferroptosis, an iron-dependent mechanism of cell death, due to their increased 
iron uptake216.  Given that Beclin 1 expression is frequently decreased across 
many human tumors, Beclin 1 could be a clinically relevant biomarker for many 
cancer patients.    
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Beclin 1 is a haploinsufficient tumor suppressor that regulates growth factor 
receptor signaling through endocytic receptor trafficking in an autophagy-
independent manner. Growth factor receptor signaling is important for regulating 
metabolic processes. Beclin 1 is also essential to the autophagic pathway. 
Reports indicate that autophagy is required for the maintenance of glycolytic 
capacity in KRAS mutant cells in vitro. However, a role for Beclin 1 in glycolysis 
has not been established. Here, we provide in vivo evidence for a role for Beclin 
1 in tumor metabolism that is autophagy-independent. We discover that Beclin 1 
alters glucose metabolism in mice on both the systemic and local tumor levels. 
Additionally, our results indicate that Beclin 1 may be a negative regulator of lipid 
metabolism. These data provide insight into the role of Beclin 1 as a tumor 






















Beclin 1 is a haploinsufficient tumor suppressor as loss of one allele leads to the 
spontaneous development of tumors in mice42,45. Reduced mRNA expression of 
Beclin 1 is associated with poor prognosis in many cancers, further supporting its 
role as a tumor suppressor. While Beclin 1 is essential for the initiation of 
autophagy and loss of this function is thought to be important for tumor initiation, 
Beclin 1 has additional autophagy-independent functions that contribute to its 
suppression of tumor progression8,46. Previous studies from our lab 
demonstrated a role for Beclin 1 in regulating growth factor receptor signaling by 
controlling the duration of time that active receptors remain within a signaling 
competent endosome compartment. As discussed in Chapter II, I have 
demonstrated that this regulation of endocytic receptor trafficking controls tumor 
proliferation in a TNBC orthotopic mouse model.  Specifically, when Beclin 1 
expression is suppressed, epidermal growth factor (EGFR) expression is 
elevated and downstream MAPK signaling is increased. Furthermore, expression 
of the iron transporter transferrin receptor (TFR1) is also elevated in these 
tumors, and both pathways contribute to proliferation.  Importantly, suppression 
of another essential autophagy gene, ATG5, does not increase proliferation or 
enhance EGFR or TFR1 expression, supporting an autophagy-independent role 
for Beclin 1 in this regulation. 
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The original hallmarks of cancer included the ability of tumor cells to evade 
apoptosis, enhance angiogenesis, sustain replicative potential, trigger invasion 
and metastasis, respond to growth signals and sustain proliferation217. More 
recently, new emerging hallmarks of cancer have been proposed that include the 
capacity for tumor cells to reprogram their metabolism218. This metabolic 
reprogramming refers to the tumor’s ability to alter sugar, fat, and amino acid 
metabolism to meet increasing energy and biosynthetic intermediate demands 
for rapid proliferation. It has been known for many years that tumor cells perform 
glycolysis at higher rates than normal cells to keep up with their energy 
expenditure and anabolic needs, known as the Warburg effect219. However, 
studies have emerged to show that not only is glucose metabolism 
reprogrammed, but glutamine and fatty acid metabolism can also be altered.  For 
example, KRAS mutant and Myc overexpressing tumors have been shown to rely 
on glutamine metabolism to support tumor cell proliferation220,221. Additionally, 
tumor cells can increase lipid content to meet metabolic demands either by 
endogenous means through de novo lipogenesis (DNL) or by increased uptake 
from exogenous sources222,223.  
 
There are many mechanisms by which tumors cells alter cellular metabolism.  Of 
relevance to Beclin 1, autophagy has recently been shown to regulate glucose 
metabolism. Jay Debnath’s group demonstrated that inhibition of autophagy in 
KRAS mutant mouse embryonic fibroblasts (MEFs) reduces glucose uptake and 
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glycolysis224.   This occurs through an autophagy-dependent regulation of GLUT1 
recycling to the cell surface that is mediated by sequestration of the RabGAP 
TBC1D5 by LC3+ autophagosomes.  While this regulation was shown in MEFs 
deficient in Atg7 and Atg5, both of which are essential for the elongation of the 
autophagophore, the involvement of other autophagy genes that have additional 
autophagy-independent functions, such as Beclin 1, has not been explored.  In 
our in vivo tumor analysis, suppression of Beclin 1 and ATG5 expression led to 
an equivalent reduction of autophagy, but increased tumor growth was only 
observed when Beclin 1 expression was reduced.  This finding supports the 
possibility that autophagy-independent functions of Beclin 1 may regulate tumor 
metabolism by alternative mechanisms to drive proliferation.  
 
In this study, I investigated the contribution of Beclin 1 to tumor metabolism in 
vivo.  Local and systemic glucose metabolism was assessed in mice bearing 
either shBECN1 or shATG5 RAS mutant TNBC tumors.  My results support an 
autophagy-independent role for Beclin 1 in the regulation of both tumor 
metabolism and systemic metabolic homeostasis and reveal a potential role for 
Beclin 1 in the regulation of fatty acid metabolism. 
 
MATERIALS AND METHODS 
Cell Lines and shRNAs. MDA-MB-231 LM2 4175 cells (LM2 cells) were 
purchased from the laboratory of Juan Massagué (Sloan Kettering). Lentiviral 
vectors containing short hairpin RNA (shRNA) targeting GFP, BECN1, and ATG5 
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were obtained from Open Biosystems (Huntsville, AL). MDA-MB-231 LM2 4175 
cells were infected with virus for each shRNA and stably expressing cells were 
selected with 2ug/mL puromycin (GoldBio).  
Animal care. 6 week old NOD/SCID mice were purchased from Jackson 
laboratories (Bar Harbor, ME). Mice were housed and cared for in the animal 
facility of the University of Massachusetts Medical School. The facility is 
approved by the Association for Assessment and Accreditation of Laboratory 
Animal Care International and is up to date on regulations of the U.S. 
Department of Agriculture, the U.S. Department of Health and Human Services, 
and the National Institutes of Health. Mice were cared for according to university 
animal care guidelines.  
Orthotopic xenograft tumor growth study. 7 week old NOD/SCID mice were 
injected with 1x106 LM2 cells expressing either shGFP, shBECN1 or shATG5 
into the 3rd mammary fat pad.  Mice were monitored twice weekly for body weight 
(g) and tumor dimensions. Tumor volume was calculated as follows: 
V=4/3π/[(LxWxH)/2].  In vivo metabolic studies were initiated at 3 weeks post 
injection to ensure similar tumor sizes between groups. Mice were euthanized 
with pentobarbital at the end of the hyperinsulinemic-euglycemic clamp study.  
 
Hyperinsulinemic-Euglycemic clamp study. Survival surgery was performed 5 
to 6 days prior to clamp experiments to place an indwelling catheter in the jugular 
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vein. Mice were fasted overnight the day before the clamp experiment (~12 
hours).   Conscious mice were continuously infused with human insulin (primed 
at 150 mU/kg body weight, followed by 2.5 mU/kg/min [Humulin; Eli Lilly, IN])225 
for 2 hrs. To maintain euglycemia, 20% glucose was infused at variable rates 
during the clamps. Whole-body glucose turnover was assessed with a 
continuous infusion of [3-3H]glucose (PerkinElmer, Waltham, MA). A bolus of 2-
deoxy-d-[1-14C]glucose (2-[14C]DG) (PerkinElmer, Waltham, MA) was 
administered at 75 min after the start of the clamp study to measure insulin-
stimulated glucose uptake in individual organs. At the end of the clamp study, 
mice were anesthetized and tissues were extracted for further analysis. 
 
Biochemical analysis and calculation. Glucose concentrations during the 
clamp study were measured using 10 µl of plasma by a glucose oxidase method. 
Plasma was analyzed on an Analox GM9 Analyser (Analox Instruments, Ltd., 
London, United Kingdom). Plasma [3-3H]glucose, 2-[14C]DG, and 3H2O 
concentrations were measured after deproteinization of plasma samples225. 
Glucose uptake in tissues was analyzed by examining 2-[14C]DG-6-phosphate (2-
[14C]DG-6-P) content in tissue homogenates. Ion exchange columns were used 
to separate 2-[14C]DG-6-P from 2-[14C]DG in supernatant from tissue 
homogenates. Plasma insulin levels were measured using an enzyme-linked 
immunosorbent assay (ELISA) kit (Alpco Diagnostics, Salem, NH).  
	 92	
Basal hepatic glucose production (HGP) was determined as the ratio of basal 
[3H] glucose infusion rate to specific activity of glucose at the end of the basal 
period225. Insulin stimulated whole body glucose turnover was determined as the 
ratio of [3H] glucose infusion rate to specific activity of glucose at the end of the 
clamp period225. The insulin-stimulated rate of HGP was determined by 
subtracting the glucose infusion rate from whole-body glucose turnover. Insulin-
stimulated glucose uptake in tissues was measured by analyzing tissue 
concentration of 2-[14C]DG-6-phosphate and the plasma 2-[14C]DG.  
Labeled palmitate and glucose uptake study. Mice were starved for 5 hours 
prior to study initiation. Following starvation, mice were injected with [14C]deoxy-
D-glucose (10 uCi; NET-328, PerkinElmer) intravenously in awake mice.  After 
25 minutes, mice were given 2-[3-3H] Palmitate (30 uCi) intravenously and blood 
samples were collected every minute for 5 minutes. At the 30-minute time point, 
mice were euthanized with sodium pentobarbital (150 mg/kg body weight). 
Tumor and lower limb muscles were removed and analyzed to measure tissue 
specific glucose and fatty acid uptake.  
Body composition and energy balance. Magnetic resonance spectroscopy 
(1H-MRS) (Echo Medical Systems, Houston, TX) was used as a noninvasive 
measurement for whole-body fat and lean masses. Metabolic cage studies were 
used to measure indirect calorimetry and energy balance parameters such as 
food/water intake, energy expenditure, respiratory exchange ratio, and physical 
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activity (TSE-Systems, Inc., Bad Homburg, Germany). TSE-Systems LabMaster 
platform was used with fully automated monitoring for food and water intake and 
activity. LabMaster cages are similar to UMMS facility cages; therefore UMMS 
bedding was used in cages to minimize animal anxiety during the experiment. 
TSE systems provide intuitive software that allows for flexible experimental 
design and data analysis.  
RPPA Analysis. Frozen pieces of three tumors of each genotype (shGFP, 
shBECN1, and shBECN1:Beclin 1) were sent to the MD Anderson Cancer 
Center Reverse Phase Protein Array (RPPA) Core Facility.  RPPA was 
performed according to their previously published protocol using the standard 
antibody list updated 3. 
Immunoblotting. Frozen tumors were extracted on ice in Tissue Protein 
Extraction Buffer containing 1mM sodium orthovanadate, 10mM NaF and 
protease inhibitors (Complete Mini Tab). Tumor extracts containing equivalent 
amounts of protein were resolved by SDS-PAGE, transferred to nitrocellulose 
membranes, and immunoblotted as described previously161,162. Bands were 
detected by chemiluminescence using a ChemiDoc XRS+ system (Bio-Rad 
Laboratories,Hercules, CA, USA) and band intensities were quantified by 
densitometry using Image Lab (Beta 1) or Image J.  Only signals within a linear 
range were used for quantitation and signals were normalized to total protein 
and/or housekeeping genes.   
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RESULTS 
Beclin 1 and ATG5 are differentially required for glucose uptake in vivo. My 
in vivo tumor studies revealed an autophagy-independent role for Beclin 1 in the 
regulation of tumor proliferation that involves endocytic receptor trafficking 
(Chapter II).  Proliferation requires both growth factor stimuli and appropriate 
metabolic conditions to support the biosynthetic processes necessary for cell 
division to occur.  To investigate if Beclin 1 regulates tumor cell metabolism to 
support enhanced proliferation, I performed a hyperinsulinemic-euglycemic 
clamp study to evaluate tumor glucose uptake in vivo.  Mice bearing either 
shGFP, shBECN1 or shATG5 tumors were analyzed at 3 weeks of tumor growth 
because tumor size and volume was equivalent across all three tumor groups at 
this time (Figure 3.1A and 3.1B).   
Awake mice were kept euglycemic (100 mM basal glucose) while maintaining a 
hyperinsulinemic state to assay insulin stimulated glucose uptake in peripheral 
tissues and tumors (Figure 3.2A, clamp). Hepatic glucose production was 
suppressed following glucose infusion to ensure that all glucose measurements 
were from the exogenous glucose source (Figure 3.2B, clamp).  Following the 
clamp study, tumors and peripheral insulin-sensitive tissues (i.e., muscle, 
adipose) were removed and glucose uptake was assessed. Glucose uptake was 
reduced significantly in shBECN1 tumors when compared with uptake in shGFP 
tumors (Figure 3.3A).  However, in contrast to published in vitro observations, 
B 
A 
Figure 3.1. Tumor growth is equivalent prior to Hyperinsulinemic-
Euglycemic Clamp study. (A) Tumor growth of orthotopic xenografts in 
NOD-SCID mice.  (B) Tumor volume of tumors during the hyperinsulinemic-




Figure 3.2. Hepatic glucose production is suppressed. (A-B) Mice with 
tumors expressing shGFP, shBECN1 or shATG5 were assayed for 
suppression of hepatic glucose production with (A) plasma glucose and (B) 
hepatic glucose production. Plasma glucose was measured with a clinical 
glucose analyzer in 10uL of blood. Hepatic glucose production was measured 





Figure 3.3. Beclin 1 depleted tumors exhibit decreased insulin 
stimulated glucose uptake.  (A) Mouse tumors expressing shGFP, 
shBECN1, or shATG5 were assayed for glucose uptake following insulin 
stimulation during a hyperinsulinemic-euglycemic clamp study. Glucose was 
measured by assessing labeled 2-[14C]DG-6-phosphate (2-[14C]DG-6-P) in 
tissues. (B) Lower limb skeletal muscle from mice with shGFP, shBECN1, or 
shATG5 tumors was assessed for glucose uptake by measuring labeled 2-
[14C]DG-6-phosphate (2-[14C]DG-6-P). n=13 for shGFP and shBECN1 tumor 
bearing mice, and n=6 for shATG5 tumor bearing mice. *p<0.05  
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glucose uptake in shATG5 tumors was equivalent to uptake in shGFP tumors 
(Figure 3.3A)224.  This difference in outcomes may reflect the fact that the in vitro 
studies were performed with Atg5-/- MEFs and the current in vivo studies were 
performed with cells with reduced, but not complete loss, of ATG5 expression. 
Glucose uptake was equivalent in other peripheral tissues suggesting that 
changes in glucose uptake were specific to the shBECN1 tumors (Figure 3.3B).  
These findings support that Beclin 1 regulates insulin-stimulated glucose uptake 
and does so by autophagy-independent mechanisms. 
 
The hyperinsulinemic-euglycemic clamp study is performed under insulin-
stimulated conditions, which may not reflect basal glucose uptake potential.   To 
determine basal rates of uptake in tumors, we assessed glucose uptake in non-
stimulated mice.  For this study, basal insulin levels were measured and 
determined to be similar in shGFP, shBECN1 and shATG5 tumor-bearing mice 
(Figure 3.4A).  Awake mice were injected with [14C]deoxy-D-glucose and tumors 
and peripheral muscle tissue were removed after 30 minutes.  Basal glucose 
uptake was variable within the shGFP and shATG5 groups and, therefore, no 
significant differences in the rate of glucose uptake were observed (Figure 3.4B).  
However, a trend toward increased glucose uptake was evident in the shBECN1 
tumors.  Additional analysis of a larger cohort of mice will be necessary to 




Figure 3.4. Basal glucose uptake is unchanged between tumors.  (A) 
Mice with tumors expressing shGFP, shBECN1, or shATG5 were assayed for 
serum insulin levels with an ELISA assay. (B) Following 5 hour starvation, 
mice with tumors expressing shGFP, shBECN1, or shATG5 were assayed for 
basal glucose uptake following injection of carbon labeled glucose,14C]deoxy-
D-glucose. Glucose uptake in tumors was measured by assessing labeled 2-
[14C]DG-6-phosphate (2-[14C]DG-6-P) in tissues. n=4 for each group, *p<0.05 
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Mice with shBECN1 tumors exhibit early signs of cancer cachexia 
syndrome 
Reduced tumor glucose uptake under insulin-stimulated, but not basal, 
conditions could represent an insulin-resistant phenotype in the tumors. Insulin 
resistance is an adaptive state that can occur in many physiologic conditions 
such as exercise and fasting226.  Insulin resistance also occurs in pathological 
states such as diabetes and cancer cachexia, a wasting syndrome227.   During 
the clamp study, two measures of systemic insulin resistance are glucose 
infusion rate and glucose turnover. Slower glucose infusion rates are suggestive 
of insulin resistance as it takes less glucose to maintain a euglycemic state. 
Glucose turnover is a systemic measure of glucose uptake. Less glucose uptake 
systemically is indicative of an insulin resistant state. Mice with shBECN1 tumors 
showed decreased glucose infusion rates, as well as decreased glucose 
turnover, when compared with mice with shGFP and shATG5 tumors (Figures 
3.5A and 3.5B), indicating that mice with shBECN1 tumors exhibit an insulin 
resistant state.   
 
Systemic insulin resistance can be driven by multiple inflammatory cytokines.  
For example, interleukin 6 (IL-6), interleukin 8 (IL-8) and tumor necrosis factor-
alpha (TNF-a) are often increased in pathologic inflammatory states, mainly 
obesity and diabetes mellitus228. In order to understand whether the insulin 
resistance profile in mice with shBECN1 tumors was driven by changes in  
C 
A B 
Figure 3.5. Mice with shBECN1 tumors exhibit an insulin resistant 
profile.  (A-B) Mice with tumors expressing shGFP, shBECN1, or shATG5 
were assayed for (A) glucose infusion rate and (B) whole body glucose 
turnover during the hyperinsulinemic-euglycemic clamp study. Whole body 
glucose turnover is calculated as the ratio between the clamp hydrogen 
labeled glucose infusion rate compared to the specific activity of plasma 
glucose in the final 30 min of  the clamp study. (C) Luminex assay assessing 
cytokine levels in mouse serum of mice with shGFP, shBECN1, or shATG5 
tumors. n=13 for shGFP and shBECN1 tumor bearing mice, and n=6 for 
shATG5 tumor bearing mice. *p<0.05 
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inflammatory cytokines, we performed a Luminex assay to measure levels of 
circulating cytokines in the tumor-bearing mice.  No significant changes in 
systemic inflammatory cytokines were observed in mice with shGFP, shBECN1, 
or shATG5 tumors, although a trend toward increased MIG and Eotaxin in 
shBECN1 tumors was observed (Figure 3.5C).  Analysis of a larger cohort of 
mice will be necessary to evaluate if these factors are upregulated in shBECN1 
tumors.   
 
Cancer cachexia syndrome is associated with insulin resistance and often seen 
in patients with end stage disease. The main sign of cancer cachexia is weight 
loss, generally due to loss of skeletal muscle and adipose tissue.  This weight 
loss is usually caused by altered metabolic processing, increased energy 
expenditure and decreased oral intake.  To explore further if Beclin 1 expression 
in tumors influences the development of cachexia, energy expenditure was 
measured in mice bearing shGFP, shBECN1, and shATG5 tumors.  To do so, 
activity, food intake and water intake were assessed in a metabolic cage study. 
While no changes in food intake were observed between the different tumor 
groups, mice with shBECN1 tumors exhibited increased energy expenditure (VO2 
consumption) in a 24-hour period when compared with mice with shGFP and 
shATG5 tumors (Figure 3.6A).  This difference in VO2 consumption was primarily 
observed during daytime hours, when mice typically are less active (Figure 3.6B).   
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Body composition was measured to evaluate changes in specific peripheral 
tissues that are commonly altered in cachexia.  No significant changes were 
identified in total body weight or lean muscle mass.  However, a trend toward 
decreased inguinal white adipose tissue (WAT) was observed in mice with 
shBECN1 tumors (Figure 3.7A and 3.7B).  Although muscle wasting is commonly 
observed in cancer cachexia, depletion of WAT usually precedes loss of muscle 
mass, indicating that mice bearing shBECN1 tumors may be in early stages of 
cachexia.  
 
shBECN1 tumors show evidence of elevated de novo lipogenesis  
Tumors can utilize fat to support rapid proliferation either through uptake of fatty 
acids from the environment or through de novo lipogenesis.  Our finding that 
mice with shBECN1 tumors tend to have reduced WAT (Figure 3.7B) suggested 
that shBECN1 tumors may utilize lipids as a metabolic source to support 
proliferation and in doing so, deplete the adipose tissue stores.  To assess lipid 
uptake in the tumors, mice were injected with 2-[3-3H] Palmitate, a saturated long 
chain fatty acid.  Unfortunately, this analysis was inconclusive due to the 
variability of the data within each tumor group (Figure 3.7C). Additional studies 
with a larger cohort of mice will be necessary to directly measure lipid uptake by 
the tumors.   
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As an alternative approach to assess lipid metabolism in the shBECN1 tumors, 
we examined our RPPA dataset for alterations in the expression of proteins that 
may drive this metabolic phenotype.  CD36, the cell surface glycoprotein that 
determines the rate of fatty acid uptake into cells, was not included in the RPPA 
analysis.  However, enzymes important for de novo lipogenesis showed elevated 
expression in shBECN1 tumors (Figure 3.7D).  Specifically, the enzyme acetyl-
CoA carboxylase 1 (ACC1) was significantly upregulated in shBECN1 tumors 
when compared with shGFP and shBECN1:Beclin 1 tumors (Figure 3.7D).  
ACC1 is a key regulator of de novo lipogenesis as it catalyzes the conversion of 
acetyl CoA to malonyl CoA, shifting fat catabolism to fat generation229,230. 
Expression of fatty acid synthase (FASN), which synthesizes palmitate from 
acetyl-CoA and malonyl CoA, was also elevated in shBECN1 tumors (Figure 
3.7D).  In contrast, phosphorylation of AMP-activated protein kinase (AMPK), an 
inhibitor of ACC1 and de novo lipogenesis, was reduced in shBECN1 tumors 
(Figure 3.7D).  The upregulation of ACC in the shBECN1 tumors (Figure 3.7E) 
was confirmed by immunoblot of additional tumors (n=7).  The upregulation of 
ACC1 and FASN and downregulation of pAMPK provides evidence that 
shBECN1 tumors may depend on lipid metabolism, in particular de novo 






Figure 3.6. shBECN1 tumor bearing mice exhibit increased energy 
expenditure. (A-B) Mice with tumors expressing shGFP, shBECN1, or 
shATG5 were assayed for metabolic activity during a metabolic cage study. A 
metabolic cage from TSE-systems was used to automatically measure 
mouse movement/activity in a 24 hours period.  Energy expenditure was 
measured as (A) total and (B) day time expenditure. *p<0.05, n=13 for 
shGFP and shBECN1 tumor bearing mice, and n=6 for shATG5 tumor 












Figure 3.7. Mice with shBECN1 tumors have decreased inguinal fat 
mass. (A-B) Mice with tumors expressing shGFP, shBECN1, or shATG5 
were assayed for body composition. Inguinal fat was measured following 
hyperinsulinemic-euglycemic clamp study. (C) Graph highlighting proteins 
involved in de novo lipogenesis that were assayed through reverse phase 
protein array (RPPA). (D) Tumor fatty acid uptake was measured under non-
stimulated conditions by measuring hydrogen labeled palmitate (2-[3-3H] 
Palmitate) after a 5 minute injection. (E) Immunoblot validation of total ACC 





Our study demonstrates that Beclin 1 regulates both local and systemic glucose 
metabolism in an autophagy-independent manner and reveals a potential role for 
Beclin 1 in the of regulation lipid metabolism. Specifically, tumors with reduced 
Beclin 1 expression have decreased insulin-stimulated glucose uptake and mice 
bearing these tumors display systemic insulin resistance. shBECN1 tumor 
bearing mice also have increased daytime energy expenditure and reduced white 
adipose fat depots. Together these phenotypes are evidence of early cancer 
cachexia, a condition that occurs often at the end stage of cancer and can lead to 
patient death. We note that shBECN1 tumors have elevated expression of ACC1 
and FASN, enzymes involved in de novo lipogenesis, which may signify a 
reliance of these tumors on lipid metabolism for proliferation. Taken together, our 
data support a novel mechanism by which Beclin 1 regulates tumor progression 
and impacts cancer outcomes. 
 
Our data suggesting that Beclin 1 may play a role in regulating de novo 
lipogenesis contributes to our understanding of how Beclin 1 controls tumor 
proliferation.  The ability of tumor cells to reprogram their metabolism is a 
hallmark of cancer and is essential to support the enhanced biosynthetic activity 
necessary for rapidly dividing cells.  I observed a trend in increased basal 
glucose uptake, however this increase was modest and needs to be further 
validated.  In contrast, I identified a significant increase in the expression of 
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enzymes that control fatty acid synthesis, ACC1 and FASN, and decrease in the 
expression of phosphorylated AMPK, an inhibitor of ACC1 activity.  This “de novo 
lipogenesis signature” supports that loss of Beclin 1 expression results in the 
reprogramming of lipid metabolism.  Lipid metabolism is highly active in breast 
tumors and metastatic tumors are reported to have high levels of fatty acid 
utilization. Triple negative breast carcinoma cells generate high levels of ATP 
through fatty acid oxidation231.  Silencing of ACC1 in breast cancer cells reduces 
de novo lipogenesis and induces apoptosis, suggesting that ACC is also 
important for breast tumor survival232.  Future studies to examine de novo 
lipogenesis and its role in the proliferation of tumors with low Beclin 1 expression 
are necessary to establish the contribution of this pathway to the aggressive 
behavior of these tumors.  Of clinical relevance, an allosteric inhibitor of ACC1 
and ACC2 has been developed that suppresses fatty acid synthesis and inhibits 
non-small cell lung cancer growth in vivo233.  Tumors with low Beclin 1 
expression may be more sensitive to this targeted therapy.   
 
Our study highlights a role for Beclin 1 in the energy wasting syndrome of cancer 
cachexia234.  Mice with shBECN1 tumors have increased daytime energy 
expenditure, reduced inguinal fat mass and systemic insulin resistance, a finding 
not observed in mice with shATG5 tumors. These symptoms are often the first 
signs of cancer cachexia, which affects cancer patients in the later stages of 
disease and contributes to their morbidity and mortality. Little is known about 
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mediators of cancer cachexia, although some cytokines including TNF-α and IL-6 
are associated with cancer cachexia syndrome in different human cancers235,236.   
However these factors cannot explain all cases of cachexia and the reasons why 
some patients develop this wasting syndrome and others do not are unknown.  
Identifying factors that drive cachexia is necessary for developing approaches to 
treat these patients. Given that Beclin 1 expression is reduced across multiple 
human tumors, it could serve as a biomarker for patients that may be prone to 
the development of cancer cachexia. Future studies using mouse models of 
cachexia may help to understand how Beclin 1 influences tumor function to 
induce cancer cachexia.  Moreover, additional metabolic analyses of shBECN1 
tumors may reveal factors that control this devastating condition.    
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Summary of Findings 
BECN1 is a haploinsufficient tumor suppressor gene that is often reduced in 
multiple cancers such as breast, ovarian, and prostate. Additionally, low Beclin 1 
expression is an independent predictor of prognosis in different cancers and is 
associated with poor outcomes. Despite this, many studies have been unable to 
elucidate why a reduction in Beclin 1 expression is associated with aggressive 
tumor behavior. My work was designed to understand the implications of reduced 
Beclin 1 expression in a TNBC model in vivo. In this thesis, I present an 
explanation as to why reduced Beclin 1 expression is associated with poor 
prognosis as well as a novel therapeutic approach for TNBC. Additionally, my 
studies provide evidence of autophagy-independent roles that add to our 
understanding of Beclin 1 as a tumor suppressor, where previously this role was 
attributed solely to autophagy. My work reveals a novel mechanism for Beclin 1 
in the regulation of endocytic trafficking by regulating the recruitment of HRS to 
endosomes. HRS sorts ubiquitinated cargo to be degraded at the lysosome. I 
observed that loss of this recruitment leads to enhanced and sustained signaling 
of receptors, which enhances proliferation in vivo. This phenomenon occurs with 
both growth factor (EGFR) and nutrient (TFR1) receptors that are degraded 
through the endolysosomal machinery. As a result, tumors that express low 
levels of Beclin 1 are sensitive to inhibition of EGFR and downstream signaling 
effectors ex vivo, and respond with a reduction in overall proliferation, 
representing a possible therapeutic strategy to target these tumors in the clinic. 
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To further understand the impact of reduced Beclin 1 expression in vivo, I was 
able to show that Beclin 1 alters glucose metabolism in a hyperinsulinemic-
euglycemic clamp study. shBECN1 tumors have reduced local glucose uptake 
and have reduced systemic white adipose tissue suggesting that they use fat as 
an energy source. Additionally, I show a potential novel role for Beclin 1 in the 
negative regulation of de novo lipogenesis as shBECN1 tumors upregulate 
proteins involved in this process. Interestingly, Beclin 1 may also be a biomarker 
for cancer cachexia, in which there are few known mediators, as mice with 
shBECN1 tumors exhibit early signs of this wasting disease.  
 
My study also adds to our knowledge of the autophagy-independent functions of 
Beclin 1. Knockdown of ATG5, another essential autophagy gene that is 
important for the elongation and closure of the autophagosome, does not result 
in the same outcomes as knockdown of Beclin 1. ATG5 does not alter HRS 
recruitment to affect degradation of ubiquitinated cargos nor does it alter glucose 
metabolism at either the local or systemic levels in mice with shATG5 tumors. My 
work highlights the importance of these functions in breast cancer but these roles 
can impact other cancer types.  
  
Beclin 1 as a tumor suppressor 
Several studies support a tumor suppressive role for Beclin 1, but the 
mechanisms governing this role are still poorly understand. Heterozygous loss of 
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Beclin 1 in vivo leads to the development of lung adenocarcinomas, liver 
adenocarcinoma and lymphomas in mice. Additionally, these mice develop pre-
malignant changes in the mammary gland compared to WT matched 
controls42,45. In another model, overexpression of Beclin 1 in MCF7 cells prevents 
tumor formation in mice and suppresses proliferation in vitro, further supporting 
this tumor suppressive role65. Beclin 1 as a tumor suppressor has been 
examined in the context of autophagy. Autophagy can clear damaged protein 
and organelles that can cause cellular stress. For example, immortalized baby 
mouse kidney (iBMK) cells with reduced Beclin 1 expression show reduced 
autophagy and accumulate reactive oxygen species, p62 aggregates, and 
damaged mitochondria34,36. The authors concluded that these aggregates 
promote tumor progression when Beclin 1 expression is reduced because these 
factors can cause genomic instability. My data indicating that Beclin 1 regulates 
growth factor and nutrient receptor signaling to regulate proliferation provides 
mechanistic insight into the role of Beclin 1 as a tumor suppressor that is 
independent of its function in autophagy. Regulating the recruitment of HRS to 
endosomes, governing the degradation of receptors that are often highly active in 
cancer and controlling signaling provide a molecular mechanism by which Beclin 
1 functions as tumor suppressor.  
 
Studies using genetic mouse models carrying heterozygous loss of Beclin 1 
reached conflicting conclusions about the role of Beclin 1 as a tumor suppressor. 
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For example, heterozygous loss of Beclin 1 promotes mammary tumorigenesis in 
mice following parity and promotes WNT-1 driven tumorigenesis. On the other 
hand, in genetic models driven with either the polyoma middle T antigen (PyMT) 
or a HER2, heterozygous loss of Beclin 1 does not promote mammary 
tumorigenesis. My data showing that Beclin 1 regulates endocytic trafficking of 
certain receptors explains these different findings in Beclin 1 dependent 
tumorigenesis. Certain receptors are regulated through endolysosomal trafficking 
through HRS such as some RTKs and the Frizzled receptor family. Once 
activated, the Frizzled receptors then activate Wnt signaling downstream. It is 
possible that the enhanced mammary tumorigenesis following parity observed in 
mice was due to loss of Beclin 1 expression resulting in the reduction of 
endolysosomal degradation of the Frizzled receptors, resulting in enhanced WNT 
signaling and promotion of tumorigenesis. On the other hand, PyMT and HER2 
are not regulated in the same manner. While HER2 is endocytosed, it is resistant 
to degradation and is instead recycled to the cell surface237. Interestingly, 
heterodimerization of EGFR and HER2 leads to delayed receptor degradation 
and increased recycling of this heterodimer to the cell surface238,239. Given how 
HER2 receptor trafficking is regulated, loss of Beclin 1 expression is not likely to 
alter HER2 expression and function and is unlikely to change tumor growth in a 
HER2 model. These differences in receptor trafficking likely explain the 
discrepancies in previous studies regarding the role of Beclin 1 in the regulation 
of mammary tumorigenesis. These studies suggest that the role of Beclin 1 in 
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mammary tumor growth is context specific. However, my work reveals that the 
role of Beclin 1 in tumorigenesis is directly linked to the regulation of receptor 
trafficking. By understanding the context of how receptors are trafficked, we can 
identify signaling pathways that may be altered when Beclin 1 expression is 
reduced. To further study the regulation of receptor trafficking in vivo, I would use 
cell lines with sustained activity of different RTKs that undergo endolysosomal 
receptor degradation through HRS and examine tumor growth in vivo using a 
xenograft model. For example, I could generate shBECN1 expressing non-small 
cell lung cancer cell lines that have an activating EGFR mutation and examine 
tumor growth in NOD/SCID mice. I hypothesize that shBECN1 EGFR mutant 
cells would exhibit enhanced tumor growth due to reduced receptor degradation 
through the endolysosomal pathway compared to shGFP expressing EGFR 
mutant cells. This would further suggest that Beclin 1 regulates RTK expression 
and function of RTKs that are regulated through HRS and would also show that 
this regulation happens in other cancers in addition to breast cancer. 
 
Beclin 1 and growth factor signaling in cancer 
Growth factor receptor signaling is often aberrantly regulated in cancer 
pathogenesis. Enhanced signaling downstream of receptors such as RTKs leads 
to the activation of multiple downstream signaling pathways that promote cancer 
growth and survival. For example, both EGFR and IGF-1R activity are enhanced 
in multiple cancer types including breast cancer. Overexpression of EGFR and 
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IGF-1R are observed in over 50% and up to 46% of all TNBC respectively240,241. 
This overexpression translates to elevated receptor activity and abnormal 
signaling. While there are multiple mechanisms for this aberrant signaling, one 
mechanism includes the inability of endocytosed receptors to be degraded. For 
example, disruption of endocytic processing of EGFR by interrupting 
endoplasmic reticulum contact sites has been shown to cause delayed 
degradation and enhanced signaling downstream of the EGFR242. Additionally, 
overexpression of EGFR at the plasma membrane causes the increase of either 
homodimerization or heterodimerization, leading to enhanced kinase activity243. 
Overexpression of IGF-1R leads to enhanced signaling and can be observed 
when IGF-1R heterodimerizes with the Insulin Receptor (IR)244. The overall result 
of this enhanced receptor expression is the upregulation of downstream 
signaling, which is often observed in aggressive breast cancer subtypes. My 
work provides a novel mechanism into how the activity of certain signaling 
pathways can be enhanced in cancer and is the first to show that Beclin 1 
regulates growth factor signaling in vivo. Taken together, my work emphasizes 
the importance of regulating growth factor signaling in cancer.  
 
In my orthotopic xenograft model, I have shown that loss of Beclin 1 results in 
enhanced signaling downstream of the EGFR receptor because of the ability of 
Beclin 1 to regulate HRS recruitment to the endosome. Although the 
endolysosomal degradation of other RTKs such as IGF-1R, PDGFR and the IR is 
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regulated in a similar manner to EGFR, the ubiquitin ligases responsible for 
ubiquitinating these receptors are different. As mentioned previously, c-Cbl, a 
member of the Cbl family of ubiquitin ligases, ubiquitinates EGFR, while Nedd4, 
an E3 ubiquitin ligase, ubiquitinates IGF-1R87,90,91. However, both of these 
receptors (EGFR and IGF-1R), when ubiquitinated, are recognized by HRS and 
sorted for degradation. Therefore, I hypothesize that in other breast cancer 
models with reduced Beclin 1 expression, enhanced signaling of these receptors 
(IGF-1R, PDGF, or Insulin) may also be due to diminished HRS recruitment to 
endosomes. I can test this in vitro by stimulating cells with the respective ligands 
of these receptors and immunoblotting for changes in phospho-HRS as a 
surrogate marker for HRS recruitment to endosome. I can also use 
immunofluorescence staining to look for reduced HRS puncta. I can further test 
whether Beclin 1 can regulate the signaling of these receptors in vivo by 
performing IPs for HRS and immunoblotting for phospho-tyrosine expression in 
shBECN1 expressing tumors, specifically in tumor models that show enhanced 
signaling downstream of these receptors. Furthermore, I can explore the ability of 
Beclin 1 to regulate HRS recruitment to endosomes to modulate RTK signaling 
by examining other cancers. Beclin 1 expression is reduced in multiple 
aggressive tumor types including oral tongue squamous cell carcinoma, prostate, 
ovarian, gastric cancer and hypopharyngeal cancer59,62-64. Therefore, it is 
important to explore whether the regulation of signaling by Beclin 1 in breast 
cancer is a conserved mechanism across multiple cancers. 
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My study models the reduction of Beclin 1 expression observed in many cancers 
that results in disruption of the PI3KC3 interaction. However, Beclin 1 can 
undergo post-translational modifications that interrupt its ability to interact with 
PI3KC3. For example, AKT phosphorylates Beclin 1 at the S295 site and EGFR 
phosphorylates Beclin 1 at Y229, Y233 and Y352 sites to disrupt the interaction 
of Beclin 1 and PI3KC3245,246. In normal physiology, this short-term regulation 
may serve as a way to regulate the duration of signaling downstream of active 
receptors. However, this regulation may provide an advantage to cancer cells to 
promote sustained activation of receptor signaling. Beth Levine’s group 
generated Beclin 1 mutant phosphorylation constructs that either mimic Beclin 1 
phosphorylation (Beclin 1 EEE) or are unable to be phosphorylated (Beclin 1 
FFF).  The Beclin 1 EEE phosphomimetic was shown to increase proliferation 
and tumor growth in non-small cell lung cancer model while the Beclin 1 FFF 
mutant suppressed tumor growth246. This group concluded that the functional 
outcome of the phosphomimetic Beclin 1 mutant was due to a deregulation of 
autophagy. However, I hypothesize that the Beclin 1 phosphomimetic (Beclin 1-
EEE) reduces HRS recruitment to endosomes and results in sustained signaling 
downstream of growth factor receptors which promotes tumor growth. One way 
to test this hypothesis is to generate shBECN1 rescue cells that express the 
Beclin 1 EEE mutant and examine whether these cells, when stimulated with 
EGF, exhibit reduced pHRS via immunoblot or reduced HRS puncta via IF. I can 
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also stimulate cells that express this mutant to explore whether EGFR signaling 
is sustained.  Since these Beclin 1 mutants were only explored in the context of 
autophagy, it would be important to elucidate whether or not these mutants 
affects endocytic receptor trafficking thereby affecting receptor signaling. If the 
Beclin 1 EEE or FFF mutant alter receptor signaling in vitro, it would be important 
to explore these mutants in vivo to further examine the role of Beclin 1 in the 
regulation of growth factor signaling and tumor growth.  
 
Beth Levine’s group also generated a TAT-Beclin 1 peptide that was shown to 
increase autophagy and reduce tumor growth in a xenograft model247. The TAT-
Beclin 1 peptide contains 11 amino acids from the evolutionary conserved 
domain of Beclin 1 and an 11 amino acid sequence from HIV that allows it to be 
cell permeable248. This peptide increases autophagy in a dose dependent 
manner in a breast cancer cell line and is thought to activate autophagy in a 
canonical manner as treatment of shBECN1 or shATG7 cells with this peptide 
results in a reduction of LC3 puncta, indicating reduced autophagy248. Beth 
Levine’s group hypothesized that TAT-Beclin 1 may exert its affects on 
autophagy by inhibiting the interaction of Beclin 1 and Golgi associated plant 
pathogenesis-related 1 (GAPR-1) which associates with the golgi complex, 
thereby releasing Beclin 1 from the golgi to function in autophagy248. However, 
they did not explore whether TAT-Beclin 1 could alter endocytic receptor 
degradation. First it would be important to determine whether the TAT-Beclin 1 
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peptide induces endocytic receptor degradation.  If so, then it would be of interest 
to use this peptide to explore the novel role of Beclin 1 in the regulation of HRS 
recruitment in vitro and in vivo.  
 
In my studies I use an ex vivo approach to treat tumor fragments with different 
RTK and downstream signaling inhibitors and monitor proliferation through IHC. 
Using this approach I was able to determine that low Beclin 1 expressing 
mammary tumors are sensitive to both Lapatinib and PD98059, and exhibit 
reduced proliferation in the presence of these drugs. Using this technique, I can 
use other inhibitors of RTKs to screen low Beclin 1 tumors for reduced 
proliferation following treatment. This is a great platform to screen different 
inhibitors to develop novel treatment approaches for multiple cancer types that 
have reduced Beclin 1 expression. Additionally, drug treatments that result in 
reduced proliferation ex vivo can be used to screen for efficacy in shBECN1 
tumors in vivo. Orthotopic xenograft studies can be used to examine tumor 
growth regression upon drug treatment as well as determine an adequate drug 
dosing schedule that is reasonable for human use249.  
  
Beclin 1 and TFR1 in Cancer 
Iron is an essential element that is important for multiple cellular enzymes that 
function in cellular metabolism and cellular proliferation.  Given this critical 
requirement, cancer cells have generated mechanisms to increase intracellular 
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iron stores. The transferrin receptor  (TFR1) is the major regulator of iron uptake 
into the cell. Many cancers including breast, bladder and lung cancer have 
increased TFR1 expression250.  Conversely, iron transport out of the cell is 
mediated by the transporter ferroportin and consequently, ferroportin expression 
is reduced in many cancers including breast251,252. This mechanism employed by 
cancer cells to regulate both iron influx and efflux allows for iron levels to remain 
elevated, which facilitates rapid proliferation. For example, breast tumors have 
elevated levels of TFR1 expression and reduced expression of ferroportin, 
supporting a tumor microenvironment that has elevated iron levels compared to 
normal tissue251. Additionally, it was observed that breast tumors have an iron 
gene regulatory signature that can predict patient outcomes253. Our data shows, 
for the first time, that Beclin 1 can regulate TFR1 expression in vivo. Given that 
TFR1 regulates iron uptake into cells, one logical question would be to determine 
whether the proliferation phenotype findings observed in shBECN1 tumors are 
sensitive to iron chelation. Studies suggest that iron chelation can have anti-
tumor effects in vivo, therefore it would be of interest to use iron chelators in the 
orthotopic xenograft model to see if we can reduce proliferation in shBECN1 
tumors, thereby inhibiting tumor growth254. This could serve as a new mechanism 
to treat low Beclin 1 expressing tumors that have elevated TFR1 expression.  
 
Our studies from Chapter II provide a novel mechanism by which TFR1 
expression is regulated by endolysosomal degradation. Previously it was shown 
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that the iron-responsive proteins 1 & 2 regulate TFR1 mRNA expression. 
However, previous studies suggest that the endolysosomal pathway can also 
regulate TFR1 protein expression. TFR1 is ubiquitinated by membrane-
associated RING-CH (MARCH) 8, a member of the MARCH family of ubiquitin 
ligases255. In Chapter II, I observed that TFR1 remains ubiquitinated in shBECN1 
tumors. I hypothesize that decreased HRS recruitment in shBECN1 tumors 
allows for the escape of ubiquitinated TFR1 that leads to the increase in TFR1 
expression. However, it would be important to look at this regulation more 
closely. Using immunofluorescence to examine colocalization of TFR1 and HRS 
would help to support a role for HRS in the regulation of TFR1 expression 
through the endolysosomal pathway. I hypothesize that shBECN1 expressing 
cells would exhibit a reduction in HRS colocalization with TFR1 compared to 
shGFP control cells.  
 
TFR1 is a very interesting candidate for anti-tumor therapy because this protein 
can be targeted to prevent iron uptake into cells or its physiological function can 
be utilized for drug delivery. As mentioned previously, iron chelators are being 
explored as a potential anti-tumor treatment because of the importance of iron in 
cellular proliferation.  However, targeting TFR1 itself is being considered as a 
potential anti-tumor therapy256. For example, mice treated with single-chain 
antibodies targeting TFR1 exhibited reduced tumor growth in a leukemic mouse 
model by reducing intracellular iron257. Transferrin (TF) is the ligand for TFR1 that 
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binds iron and is constitutively taken up by cells. Another line of therapy is to use 
transferrin-chemotherapeutic conjugates. For example, TF-cisplatin or TF-
doxirubicin have been used both in vitro and in vivo and are cytotoxic to cancer 
cells258. Our study suggests that Beclin 1 may be a biomarker to identify tumors 
with high TFR1 expression, which can be candidates for TF-chemotherapeutic 
conjugates. Additionally, using TF conjugated to inhibitors of downstream RTK 
signaling pathway members would be worth exploring in our tumor model. I can 
also use my ex vivo drug treatment system to determine which TF-conjugates 
are effective in multiple cancers and then use these same conjugates in vivo to 
explore their efficacy in reducing tumor growth in low Beclin 1 expressing tumors.  
 
Beclin 1, HRS and the Endolysosomal Pathway 
Several studies in lower organisms have implicated a role for Beclin 1 in 
endocytosis and have hinted at a potential role for Beclin 1 in the regulation of 
subcellular signaling50,52. In the mammalian system, the Stenmark group showed 
that the Beclin-1-PI3KC3-UVRAG interaction (Complex II) was important for 
endosomal maturation and regulation of EGFR degradation48. Our lab’s 
previously published work supports this role for Complex II as we showed that 
Beclin 1 regulates endosomal maturation and reduced Beclin 1 expression allows 
receptors to signal from immature but signaling competent endosomes. Both of 
these studies were done in an in vitro model system. My work in this dissertation 
expands on these studies and now provides a novel explanation for the 
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regulation of endocytic trafficking by Beclin 1 in vivo using a breast cancer model. 
However, as mentioned, this regulation may also be present in other cancer 
types. Additionally it provides more support for the role of Beclin 1 in the 
regulation of growth factor receptor signaling which can contribute to its role as a 
tumor suppressor.  
 
My work shows that Beclin 1 promotes the recruitment of HRS to endosomes, 
which sorts cargos for degradation in the endolysosomal pathway. By 
immunofluorescence staining, I show a reduction in HRS puncta in shBECN1 
cells as compared to control cells. Given that HRS is recruited to early 
endosomes and that our previous work shows that Beclin 1 regulates early 
endosomal maturation, using co-staining techniques with other endosomal 
markers would be necessary to confirm that the HRS puncta I visualized 
represent early endosomes. I can use Rab5, which is a marker of early 
endosomes, to confirm that the HRS is recruited to the early endosome. I can 
also stimulate breast carcinoma cells expressing shGFP or shBECN1 with EGF 
and perform an IP with HRS. I can then blot for early endosomal markers such as 
Rab 5 or early endosomal antigen 1 (EEA1) to show that there is decreased 
interaction between HRS and early endosomal markers in shBECN1 expressing 
breast carcinoma cells. This would help to further support a role for Beclin 1 in 
the endosomal recruitment of HRS. Signal transduction through active receptors 
and degradation of these receptors through HRS recruitment is a dynamic 
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process. One caveat to my study is that I examine recruitment of HRS in a short 
time course of either 10 to 15 minutes following EGF stimulation. Therefore 
additional studies are required to further look at the recruitment of HRS and 
longer time courses may be necessary to examine this dynamic process.  
 
As mentioned previously, HRS is a member of the endosomal-sorting complex 
required for transport (ESCRT) machinery. This machinery sorts cargos into 
intraluminal vesicles (ILVs) that go on to form multivesicular bodies (MVB) which 
fuse with lysosomes to degrade their content. HRS is a member of ESCRT-0. I 
could examine TSG101 recruitment to HRS puncta since TSG101 is member of 
the ESCRT-I complex and is recruited to endosomes after ESCRT-0. I 
hypothesize that shBECN1 expressing cells would exhibit a reduction in TSG101 
positive staining as TSG101 is recruited to endosomes by HRS. To confirm that 
this is happening in vivo, I could use Amnis Flow Cytometry Flowsight to examine 
freshly dissociated tumor cells for colocalization of different markers such HRS, 
TSG101 and Rab5. Amnis Flow cytometry Flowsight is an imaging flow 
cytometer that takes images of individual cells and allows for the localization and 
quantification of colocalized proteins in single cells.  
 
HRS is recruited to early endosomes in a PI3P-dependent manner100,102. 
Previously our lab showed that loss of Beclin 1 leads to a reduction in growth 
factor stimulated PI3P production that results in delayed maturation of 
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endosomes131. We also observed a reduction in the recruitment of early 
endosome antigen 1 (EEA1) to early endosomes in shBECN1 cells. EEA1 is also 
recruited in a PI3P-dependent manner131.  In my work, I hypothesize that HRS 
recruitment to the endosome is reduced in shBECN1 expressing LM2 cells 
because of a reduction in PI3P. However, it would be important to show that this 
regulation is occurring in the LM2 shBECN1 cells and shBECN1 tumors. To 
determine if reduced recruitment of HRS is due to reduced PI3P, I could examine 
the recruitment of other PI3P-dependent proteins to the endosome as our lab 
previously showed in another breast cancer cell line131. EEA1 is an early 
endosomal protein that is recruited to the endosome by the binding of its FYVE 
domain to PI3P259,260. Since Beclin 1 regulates PI3P production, I would expect 
reduced EEA1 endosomal recruitment in shBECN1 cells compared to shGFP 
control cells. Although we previously showed this finding in another cell line, it 
would still be of interest to show that this happens in the LM2 shBECN1 cells. 
These results would support a hypothesis that the reduction in HRS recruitment 
to the endosome is due to reduced PI3P production.  
 
As I mentioned previously, HRS initiates the MVB pathway by recognizing and 
binding ubiquitinated cargos destined for sorting into ILVs111,261. This signal 
allows for the sequential recruitment of other ESCRT complexes. This key step of 
ubiquitination has been shown to be essential for degradation of multiple RTKs 
including the EGFR262. In my work, I also show that TFR1 remains ubiquitinated 
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in shBECN1 tumors.  I hypothesize that ubiquitinated receptors escape 
degradation, which causes elevated receptor expression levels. It is important to 
investigate the ubiquitination of other receptors both in vivo and in vitro to further 
support a role for Beclin 1 in regulation of HRS and the degradation of different 
growth factor and nutrient receptors. In order to examine whether proteins 
escape degradation by remaining ubiquitinated, I could stimulate cells expressing 
shBECN1 with EGF ligand (or other receptor ligands), treat with a deubiquitinase 
inhibitor such as N-ethylmaleimide (NEM), perform an IP for EGFR (or other 
RTKs), and blot for ubiquitin. Compared to shGFP expressing cells, shBECN1 
expressing cells may exhibit a prolonged ubiquitination of the EGFR receptor. 
This data would support that reduced Beclin 1 expression allows for enhanced 
signaling because receptors escape degradation and remain ubiquitinated. I can 
also express a mutant EGFR construct in the LM2 cells that is unable to be 
ubiquitinated. The Sorkin group generated a EGFR construct that has either 15 
or 16 lysine-arginine (KR) mutations in the kinase domain of EGFR that prevent 
EGFR from being ubiquitinated263. I can express this mutant EGFR in EGFR 
knockout LM2 breast carcinoma cells that have reduced Beclin 1 expression and 
stimulate with EGF to examine downstream signaling. In shGFP cells, this 
mutant EGFR construct should exhibit reduced degradation and sustained 
signaling to a greater extent compared to shBECN1 expressing cells. shBECN1 
cells may still exhibit an increase in signaling but the fold change will not be as 
significant as the shGFP control cells. I can also use these EGFR knockout cells 
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that express the EGFR ubiquitin mutant in vivo to examine tumor growth. I expect 
that shGFP LM2 cells that express the EGFR ubiquitin mutant will exhibit a more 
significant enhancement in EGFR signaling and increased tumor growth. LM2 
shBECN1 cells that express the EGFR ubiquitin mutant in vivo may exhibit 
increased growth however as stated previously, the fold change may not be a 
significant as observed for the shGFP tumors.   
 
Autophagy-Independent/alternative Roles for Beclin 1 in Cancer 
Autophagy can suppress tumor initiation and progression through multiple 
mechanisms. Autophagy can help to clear damaged proteins and organelles to 
suppress tumorigenesis by reducing reactive oxygen species, which promotes 
genomic instability. As stated previously, reduction of Beclin 1 and Atg5 
expression in iBMK cells was shown to lead to the accumulation of both p62 and 
damaged mitochondria, resulting in elevated ROS and oxidative stress, which in 
turn promotes DNA damage34,36. Autophagy can also prevent malignant tumor 
formation; mice with systemic mosaic deletion of Atg5 or liver specific knockout 
of Atg7 develop liver adenomas, which are non-malignant tumors, and 
accumulate ROS37.  However, these benign liver tumors fail to progress to 
hepatocellular carcinoma despite having increased ROS levels and genomic 
instability37. On the other hand, mice heterozygous for Becn1 develop multiple 
spontaneous malignancies including lung adenocarcinoma, liver 
adenocarcinomas and lymphomas. This difference in tumor development 
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between essential autophagy genes suggests that Beclin 1 has autophagy-
independent or autophagy alternative functions that are required for cancer 
development.  
 
My orthotopic xenograft studies indicate that shBECN1 expressing tumors exhibit 
increased tumor growth compared to shATG5 expressing tumors. I show that 
autophagy is equivalently reduced in these tumors, however there is a difference 
in tumor growth. shBECN1 expressing tumors also exhibit an increase an 
EGFR/MAPK signaling due to diminished recruitment of HRS which prevents 
endolysosomal degradation of EGFR thereby promoting sustained signaling. This 
data suggest that it is the endolysosomal regulation by Beclin 1 that promotes 
enhanced tumor growth. I hypothesize that shATG5 tumors do not exhibit 
increased tumor growth because ATG5 does not regulate endolysosomal 
degradation. It would be interesting to explore this further by manipulating 
endolysosomal degradation in shATG5 expressing cells. I can express an HRS 
FYVE domain deletion mutant to perturb endolysosomal degradation. As stated 
previously, HRS is recruited to endosomes through its FYVE domain that binds 
PI3P. Using this mutant, I could compare tumor growth of shATG5 (autophagy 
deficiency) and shATG5:HRS-FYVE domain deletion (autophagy and 
endolysosomal degradation deficient) cells. I hypothesize that shATG5:HRS-
FYVE domain tumors would exhibit increased tumor growth compared to 
shATG5 and shGFP control tumors because receptor degradation would be 
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disturbed. Expressing the HRS mutant in shATG5 cells may allow the shATG5 
tumors to behavior more similarly to shBECN1 tumor because they will now 
exhibit defective endolysosomal degradation.  
 
My work highlights a novel role of Beclin 1 in the regulation of growth factor and 
nutrient receptor signaling in vivo that is autophagy-independent. As shown in 
Chapter II, knockdown of Beclin 1 or ATG5 results in equivalent reduction in 
autophagy. However, when I examined the functionality of this loss through 
tumor growth and proliferation, I note that reduction of ATG5 does not result in 
enhanced tumor growth or changes in proliferation compared to control tumors. 
Additionally, ATG5 does not regulate HRS recruitment to endosomes and 
therefore does not alter growth factor or nutrient receptor signaling. This finding 
helps to justify a role for Beclin 1 in cancer that is autophagy-independent.  
 
In my study I knockdown Beclin 1 expression which affects both Complex I 
(autophagy) and Complex II (autophagy-independent). In order to determine if 
the autophagy-independent phenomenon I observed is regulated by Complex II, 
it would be important to investigate these complexes separately. I could knock 
down either ATG14 or UVRAG independently to examine their role in HRS 
recruitment. Based on my work, I hypothesize that Complex II, with UVRAG, 
mediates the recruitment of HRS to endosomes by Beclin 1.  However, one 
caveat to this approach is that ATG14 and UVRAG are needed for complex 
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stability and knockdown of either of these proteins results in a reduction of Beclin 
1264. It may be possible to prevent changes in Beclin 1 expression by targeting 
regulators of ATG14 or UVRAG. One group showed that Dapper 1 (Dpr1), a 
Dishevelled (Dvl)-interacting protein that can prevent both canonical and non-
canonical WNT signaling, can regulate autophagy by enhancing the interaction of 
Complex I with Beclin 1, PI3KC3, and ATG1413. By targeting Dapper 1, I could 
reduce the interaction of Beclin 1 with ATG14 and increase the interaction of 
Beclin 1 with UVRAG. UVRAG and ATG14 bind Beclin 1 through its coiled-coil 
domain (CCD), however studies show that UVRAG has a stronger affinity for 
Beclin 1 and can out compete ATG14. Recent biochemical work has aimed to 
weaken the Beclin 1/UVRAG interaction by mutating the CCD of UVRAG265. 
These mutations help to enhance the binding of Beclin 1 to ATG14.  As a result, 
this mutant causes an increase in Complex I activity, which mediates autophagy, 
but has reduced endocytic receptor trafficking. This UVRAG CCD mutant would 
be interesting to explore in future experiments. I hypothesize that expression of 
the UVRAG CCD mutant would cause a reduction in endocytic receptor 
degradation, while maintaining autophagy. In contrast, silencing Dapper 1 would 
increase Complex II activity, which would enhance recruitment of HRS to early 
endosomes and promote receptor degradation, resulting in reduced receptor 
signaling.  Both of these methods would allow me to analyze HRS endosomal 
recruitment in a complex dependent manner.  
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Beclin 1 interacts with UVRAG and ATG14 through the coiled coil domain. This 
interaction with UVRAG or ATG14 regulates the functional outcomes of Beclin 1. 
As stated previously, Beclin 1 is a haploinsufficient tumor suppressor and 
expression of Beclin 1 is reduced in multiple cancer types. Given the reduction of 
Beclin 1, this begs the question, what regulates Beclin 1 complex formation with 
UVRAG or ATG14 in a setting of reduced Beclin 1 expression? It is important to 
explore this regulation closer to understand the role of Beclin 1 in cancer. I have 
shown that Beclin 1 regulates endocytic receptor trafficking by regulating HRS 
recruitment. I could stimulate cells with EGF and perform an IP with Beclin 1 and 
blot for UVRAG and ATG14. I hypothesize Beclin 1 regulates endocytic 
trafficking through Complex II. Therefore cell stimulated with EGF ligand may 
show an increased interaction between UVRAG and Beclin 1. Additionally, I 
could initiate autophagy in the same cells and examine whether this now 
increases the interaction of ATG14 and Beclin 1. I hypothesize that in the setting 
of low Beclin 1 expression, all Beclin 1 interacts with either Complex I or 
Complex II. However, both autophagy and endocytic receptor signaling can occur 
in a disease state. For example, RAS transformed cancer cells have increased 
autophagic activity and endocytic receptor signaling224. 
 
Recent work has generated inhibitors of PI3KC3 (VPS34) to treat cancer by 
inhibiting autophagy266-268. PI3KC3 inhibitors were shown to have antitumor 
effects on cancer cell lines and synergize with mTOR inhibitors to block 
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proliferation268. Although VPS34 inhibitors may be useful for inhibiting autophagy 
in some cancers, they may not work well for others. In the setting of low Beclin 1 
tumors, it is possible that adding a VPS34 inhibitor may worsen prognosis as this 
would lead to less HRS recruitment because of a reduction in PI3P. This would 
further suppress the degradation of both growth factor and nutrient receptors 
resulting in sustained signaling. However, if the downstream signaling is known, 
using a VPS34 inhibitor to reduce autophagy in combination with the inhibitors of 
downstream effectors is worth exploring in future experiments. My pilot studies 
suggest that knockdown of VPS34 in breast tumor cells causes sustained and 
enhanced signaling following IGF-1 ligand treatment. It would be interesting to 
explore combination therapy in these cells. I hypothesize that dual inhibition of 
VPS34 and downstream signaling effectors such as MEK, ERK, PI3K, or AKT 
would be cytotoxic to cancer cells because both the autophagy pathway and 
growth factor signaling advantage would be inhibited. However, it would be 
important to first identify which signaling pathways are elevated in different 
cancer cell lines to determine which inhibitor to use in combination with a VPS34 
inhibitor.  
 
Metastasis and Tumor Microenvironment 
Our study supports previous work that shows that Beclin 1 suppresses 
tumorigenesis and proliferation58,59.  In this study we explore tumor progression 
in an in vivo model of breast tumor growth. However, it is important to explore a 
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role for Beclin 1 in tumor metastasis, because metastatic burden often leads to 
patient demise. In my study I use LM2 cells, which are a variant of MDA-MB-231 
cells that were selected for their ability to metastasize to lung269. However, to 
observe metastatic lung lesions, survival surgery is necessary. Our previous 
work in breast carcinoma cells in vitro showed that low Beclin 1 expressing cells 
have both sustained AKT activation following IGF-1 ligand stimulation and 
enhanced invasion in a 2D Transwell Matrigel assay131. AKT signaling promotes 
tumor cell invasion which is an important initial step in the metastatic 
cascade270,271. I hypothesize that mice with low Beclin 1 expressing tumors will 
have increased metastatic burden. Using different cancer cell lines, I could test 
metastatic burden following survival surgery. In this model I could look at cancer 
progression (xenograft tumor growth) and metastasis (survival surgery) in 
multiple cancer cell lines with reduced Beclin 1 expression. It is also important to 
assess low Beclin 1 expressing tumors in a syngeneic model. One model I could 
use would be the 4T1/67nr mammary cell model in which 4T1 is the metastatic 
counterpart of the 67nr non-metastatic cell line272,273. Using the 4T1 and 67nr 
mammary cells derived from BALB/c mice, I could test a role for Beclin 1 in the 
promotion of metastasis by examining metastatic burden in BALB/c mice with 
4T1 shBECN1 tumors. I can also assess the ability of Beclin 1 to regulate the 
transformation of a non-metastatic cell line to a metastatic cell line by exploring 
the 67nr cells. In addition to survival surgery, another way to examine metastatic 
burden would be to use a luciferase reporter cell line. I could then use a non-
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invasive approach to observe metastasis through imaging. It will also serve as a 
way to detect early metastatic lesions. 
 
Our study shows that low Beclin 1 expressing tumors have elevated TFR1 
expression. However, in in vitro studies performed with shBECN1 cells, no 
increase in TFR1 expression was observed when compared to control shGFP 
cells. These data suggest that the tumor microenvironment may play a role in the 
modulation of TFR1 expression exhibited in shBECN1 tumors. Given the 
importance of the supporting cells in the tumor microenvironment, it is important 
to investigate their role in promoting changes in TFR1 expression. For example, 
macrophages can uptake, store, and release iron into the microenvironment to 
modulate iron metabolism274. My model uses NOD/SCID mice, which are 
immunocompromised but still have detectable macrophages275. It would be 
important to assess the contribution macrophages provide to TFR1 expression 
regulation. It is possible that both the tumor microenvironment and effects of low 
Beclin 1 expression synergistically impact TFR1 expression and function.  
 
Iron regulatory proteins 1 and 2 (IRP1/IRP2) regulate TFR1 mRNA expression. 
Specifically, in low iron conditions IRPs bind iron response elements (IREs) in 
TFR1 mRNA to stabilize the mRNA and in high iron concentrations these 
proteins dissociate from TFR1 mRNA to destabilize the mRNA promoting 
degradation276. While iron regulates IRP activity, other stimuli can also influence 
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IRPs such as hypoxia. IRP-2 RNA binding activity is induced in hypoxic 
conditions in HEK293 cells due to post-translational regulation277. As stated 
previously, shBECN1 expressing LM2 cells do not exhibit increased TFR1 
expression in vitro, whereas shBECN1 expressing tumors have increased TFR1 
expression in vivo. Given that IRPs bind to IREs in TFR1 mRNA, hypoxia may be 
able to induce TRF1 expression. The oxygen tension varies in different regions of 
tumors and certain areas are more hypoxic than others. Therefore, it is important 
to assess the affect of hypoxic induction of TFR1 expression in cells. shBECN1 
expressing LM2 cells can be cultured in hypoxic conditions to examine changes 
in TFR1 protein expression. It is possible that shBECN1 cells are more sensitive 
to hypoxic induction of TFR1 expression compared to shGFP control cells. Low 
oxygen tension in rapidly proliferating shBECN1 expressing tumors could drive 
increased TFR1 expression.  The difference in oxygen content in vivo compared 
to in vitro may help to explain the discrepancy in TFR1 expression in low Beclin 1 
expressing cells in vitro and tumors in vivo.  
 
Beclin 1 in Tumor Metabolism 
Cancer cells are efficient at metabolic reprogramming to create an excess of 
building blocks to support rapid proliferation and enhanced growth.  This 
requirement to alter cellular metabolism has now been considered an additional 
“Hallmark of Cancer”218. In addition to glucose utilization, cancer cells have been 
shown to rely on glutamine or fatty acids to support cellular processes. For 
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example, T cells that upregulate the transcription factor c-myc have elevated 
glutamine utilization and concordantly, deprivation of glutamine in these cells 
reduces their capacity to proliferate278. Additionally, cancer cells upregulate 
multiple genes that are important for lipid biogenesis and exhibit high levels of fat 
utilization279. In my work, I show that tumors with low Beclin 1 expression have 
reduced insulin-stimulated glucose uptake and that mice with these tumors 
exhibit systemic insulin-resistance. Additionally, mice with shBECN1 tumors 
exhibit reduced inguinal white fat and increased energy expenditure, symptoms 
that are early signs of cancer cachexia. These results suggest that Beclin 1 can 
alter metabolism and upon further exploration may provide a novel mechanism 
by which Beclin 1 regulates tumor biology and promotes aggressive tumor 
phenotypes.  
 
Recent work showed that autophagy can regulate glucose metabolism. Inhibition 
of autophagy in KRAS mutant mouse embryonic fibroblasts (MEF) reduces 
glucose uptake and glycolysis224. However, in my work I observe that RAS 
mutant tumors with low Beclin 1 expression have reduced glucose uptake while 
low ATG5 expressing tumors maintain glucose uptake. One explanation for this 
difference is that Jay Debnath’s group used a complete knockout of autophagy 
genes Atg7 and Atg5. However, my study uses shRNA to reduce Beclin1 and 
ATG5 expression.  Maintenance of some level of protein expression may allow 
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for some Beclin 1 and ATG5 specific functions to occur which may explain the 
difference in the glucose uptake phenotype observed in my study.  
 
While preliminary, my data suggest a novel role for Beclin 1 in de novo 
lipogenesis, a lipid pathway that is often upregulated in multiple cancer types. 
shBECN1 tumors appear to have elevated ACC1 and FASN expression, 
enzymes that are essential for de novo lipogenesis, as well as low pAMPK S345 
expression. AMPK phosphorylates ACC1 to inhibit lipid metabolism280. To further 
understand whether Beclin 1 has a novel function in de novo lipogenesis, an 
investigation of lipid metabolism in Beclin 1 deficient cells and tumors is 
warranted as it could provide novel insight into Beclin 1 function in the aggressive 
behavior of tumors. Acetate incorporation into different lipid products such as 
triglycerides or phospholipids can be used to assess de novo lipogenesis. 
Additionally, I can probe for the upregulation of other proteins that are important 
for de novo lipogenesis such as ATP-citrate lyase (ACYL) which converts citrate 
to Acetyl-CoA, the substrate for fatty acid synthesis279. De novo lipogenesis is of 
clinical interest as inhibitors of ACC1 and FASN have been used to inhibit 
proliferation in cancer cells281,282. Exploration of ACC1 inhibitors in my ex vivo 
drug analysis may reduce proliferation in shBECN1 tumors and can potentially be 
used as a novel therapeutic treatment for low Beclin 1 expressing tumors. It is 
possible that Beclin 1 exerts its effects on tumor metabolism by modulating 
multiple metabolic pathways. In order to examine multiple metabolic pathways, 
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metabolomics profiling through liquid chromatography mass spectrometry can be 
performed. This technique can also provide more evidence for a role of Beclin 1 
in de novo lipogenesis as well as other metabolic pathways that can be exploited 
for cancer therapy.   
 
Deregulation of metabolism is present in multiple pathogenic diseases including 
cancer. My studies in Chapter III suggest that mice with shBECN1 tumors exhibit 
early signs of cancer cachexia, a wasting disease present in end stage cancer 
that is a major cause of mortality and morbidity. Patients with cancer cachexia 
experience metabolic disturbances such as insulin resistance, muscle wasting, 
fat loss, and increase energy expenditure283. While my results are preliminary, it 
is important to address the role of Beclin 1 in the cancer cachexia phenotype as 
Beclin 1 may serve as biomarker for this disease in which few biomarkers exist. 
There are several rodent models of cancer cachexia such as the Yoshida ascites 
hepatoma rat model, a lung cancer model and murine colon cancer model284-286.  
I could use these models to examine the progression of cancer cachexia in mice 
with shBECN1 tumors compared to control mice. Moreover, studying the role of 
Beclin 1 in cancer cachexia may provide novel therapeutic strategies for this 





Significance of Findings 
Beclin 1 is a predictor of prognosis in multiple cancer types but the role of Beclin 
1 in these aggressive cancers has yet to be identified.  Additionally, studies that 
focus on Beclin 1 attribute its function in cancer to autophagy without 
acknowledging its autophagy-independent functions. In my study, I have found 
that Beclin 1 is able to control the expression and function of both growth factor 
and nutrient receptors by regulating HRS recruitment to endosomes in an 
autophagy-independent manner. In regard to a TNBC model, I have shown that 
EGFR signaling is elevated in this breast cancer subtype and tumors with this 
aberrant signaling are sensitive to inhibitors of this pathway. My work also 
identifies a potential role for Beclin 1 in lipid metabolism that may provide an 
approach for treatment. Overall my study provides future strategies for the 
treatment of low Beclin 1 expressing breast tumors with the goal of improving 
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In Chapter II, I showed that loss of Beclin 1 expression in a triple negative breast 
cancer (TNBC) cell line resulted in enhanced tumor growth and proliferation. I 
demonstrated that Beclin 1 regulates HRS recruitment to endosomes to 
modulate growth factor and nutrient receptor degradation. To understand further 
the mechanism by which low Beclin 1 expression promotes tumor growth, I 
performed RNA-sequencing on 4 shGFP and 4 shBECN1 tumors to identify 
differentially expressed genes. RNA was extracted from each tumor using the 
RNeasy kit (Qiagen). RNA-sequencing was performed by Applied Biological 
Material, Inc. (ABM, Canada) using single-end sequencing with a reading length 
of 75 base pairs and sequencing depth of 20 million reads/sample.  Only 53 
differentially expressed genes were identified (Appendix A, Figure 1A). 
Importantly, reduced BECN1 expression was observed in shBECN1 tumors 
(Appendix A, Figure 1A, red arrow).  
 
One of the downregulated genes in shBECN1 tumors encodes for Insulin-like 
growth factor binding protein-1 (IGFBP1), a 30 kd secreted protein that acts as a 
decoy for the IGF-1 and -2 ligands to prevent their binding to the IGF-1, IGF-2 
and Insulin (IR) receptors (Appendix A, Figure 1A, gray arrow)287,288. This target 
was of interest to us because we previously showed that Beclin 1 regulates 
growth factor receptor signaling downstream of the IGF-1R and IR and that 
reduced Beclin 1 expression in TNBC cells results in sustained and enhanced 
activation of AKT, a protein that promotes cancer cell invasion and survival131.  
	 143	
We hypothesized that a reduction in IGFBP1 expression could promote 
enhanced IGF-1R or IR signaling because IGFBP1 antagonizes their action. I 
used RQ-PCR to validate several of the up- and down-regulated genes identified 
by the RNA-Seq analysis in a larger panel of tumors and I confirmed that IGFBP1 
is a significantly down-regulated gene in shBECN1 tumors (Appendix A, Figure 
1B).  IGFBP1 protein expression was also reduced in shBECN1 tumors 
(Appendix A, Figure 1C). Furthermore, restoration of Beclin 1 expression 
increased IGFBP1 mRNA expression (Appendix A, Figure 2A and 2B). These 
findings support that Beclin 1 regulates IGFBP1 expression at the level of gene 
expression. Moreover, regulation of IGFBP1 expression may serve as another 
novel mechanism by which Beclin 1 can regulate growth factor receptor 
signaling, in addition to its function in endocytic receptor trafficking.  
 
As stated previously, the role of Beclin 1 in cancer has been attributed primarily 
to its function in autophagy. In Chapter II, we showed that Beclin 1 regulates 
growth factor receptor degradation through HRS and that this regulation is 
independent of autophagy. To determine if the regulation of IGFBP1 by Beclin 1 
is also autophagy-independent, I examined IGFBP1 expression in breast 
carcinoma cells with low ATG5 expression.  My data indicate that loss of ATG5 
expression does not alter IGFBP1 mRNA expression (Appendix A, Figure 3A and 















Figure A.1. IGFBP1 expression is reduced in shBECN1 tumors. (A) RNA 
sequencing was performed on 4 shGFP and 4 shBECN1 tumors. 53 
differentially expressed genes were identified. Red arrow indicate BECN1. 
Gray arrow represents IGFBP1. (B) Relative mRNA expression of IGFBP1 and 
BECN1 were determined by real-time quantitative PCR (RQ-PCR) in tumor 
expressing shGFP and shBECN1. The data shown represent the mean +/-
SEM mRNA expression from nine tumors. (C) Immunoblot analysis of Beclin 1 









Figure A.2. Beclin 1 regulates IGFBP1 expression. (A) Immunoblot analysis 
of Beclin 1 expression in LM2 cells expressing shGFP, shBECN1 and 
shBECN1:Beclin 1. (B) Relative mRNA expression of IGFBP1 was determined 
by real-time quantitative PCR (RQ-PCR) in LM2 cells expressing shGFP, 
shBECN1 and shBECN1:Beclin 1. The data shown represent the mean +/-
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Figure A.3. ATG5 does not regulate IGFBP1 expression. (A) Relative 
mRNA expression was determined by real-time quantitative PCR (RQ-PCR) in 
LM2 cells expressing shGFP, shBECN1 #1, shBECN1 #2, shATG5 #1 and 
shATG5 #2. The data shown represent the mean +/-SEM mRNA expression 
from three independent experiments. (B) Immunoblot analysis of IGFBP1 
expression in shGFP, shBECN1 #1, shBECN1 #2, shATG5 #1 and shATG5 #2 
LM2 cells. (C) Immunoblot analysis of shGFP and shATG5 tumors. The data 
shown in the graph represent the mean +/-SEM expression of six tumors from 

















observed in a lung carcinoma cell line (Appendix A, Figure 3C and 3D). 
Furthermore, analysis of ATG5 deficient tumors showed no change in IGFBP1 
protein expression when compared to control shGFP tumors (Appendix A, Figure 
3E). These results suggest that Beclin 1 regulates IGFBP1 expression in an 
autophagy-independent manner.  
 
Given that IGFBP1 can negatively regulate IGF-1R signaling it was important to 
determine whether restoration of IGFBP1 expression could suppress the growth 
of shBECN1 tumors.  To do so, an IGFBP1-myc tag cDNA was cloned into the 
pCDH-puro lentiviral plasmid to infect shBECN1 cells.  Beclin 1 knockdown cells 
were generated using a neomycin-selected shRNA for this study. Cells co-
expressing shBECN1 and either empty pCDH or pCDH-IGFBP1 were injected 
into the mammary fat pad of NOD-SCID mice (Appendix A, Figure 4A). 
Overexpression of IGFBP1 in shBECN1 tumors inhibited tumor growth to shGFP 
tumor levels (Appendix A, Figure 4B). Examination of PH3 staining in 
shBECN1:IGFBP1 tumors revealed that restoration of IGFBP1 expression in 
shBECN1 tumors reduced proliferation to the level of proliferation observed in 
shGFP tumors (Appendix A, Figure 4C). Together these results indicate that the 
reduction of IGFBP1 expression in tumors with low Beclin 1 expression may 
contribute to enhanced tumor growth.  
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Previous work has shown that autophagy competent RAS transformed cells 
secrete factors that promote invasion289. Knockdown of Atg7 in RAS transformed 
mouse embryonic fibroblasts prevents the secretion of IL-6, a cytokine that 
promotes migration289.  Treatment of Atg7-/- mouse embryonic fibroblasts with 
media from autophagy-competent cells restored their capacity to invade289. Given 
that autophagy genes can govern secretion, I examined if Beclin 1 regulates 
IGFBP1 by a mechanism involving secretion of a regulatory factor.  Conditioned 
media from shBECN1 cells was used to treat shGFP cells. Interestingly, shGFP 
cells incubated in shBECN1 conditioned media for 24 hours exhibited a reduction 
in IGFBP1 mRNA expression (Appendix A, Figure 5).  This preliminary finding 
suggests that shBECN1 cells secrete a negative regulator of IGFBP1 expression. 
Additional experiments are necessary to confirm this mechanism of regulation 
and to identify this secreted factor to determine how Beclin 1 regulates IGFBP1 
expression.  
 
Our work presented in this Appendix indicates that Beclin 1 regulates IGFBP1 
expression to suppress tumor growth. Ongoing studies are needed to understand 
the role of IGFBP1 in human tumors with low Beclin 1 expression. IGFBP1 
antagonizes IGF1 and IGF2 action and prevents activation of the IGF1R and IR 
to promote cellular survival and invasion; therefore it would be an interesting 
clinical target. One hypothesis is that reduced IGFBP1 expression may increase 








Figure A.4. Rescue of IGFBP1 suppresses growth of shBECN1 tumors.  
(A) Expression of Beclin 1 and IGFBP1 in cell lines prior to mouse injection. 
(B) Tumor growth of orthotopic xenografts in NOD-SCID mice. (C) 
Representative images of Phospho-histone H3 (PH3) staining in shGFP, 
shBECN1, shBECN1:Beclin 1 and shBECN1:IGFBP1 tumors.  The data 
shown in the graphs represent the mean +/-SEM positive nuclei/high powered 
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Figure A.5. Beclin 1 regulates IGFBP1 expression through a secreted 
factor. Conditioned media (CM) from shBECN1 cells was collected and 
transferred to shGFP cells for 24 hours. Relative mRNA expression was 
determined by real-time quantitative PCR (RQ-PCR). The data shown 




receptors in a feed forward loop. However, in my studies, shBECN1 tumors do 
not exhibit increased IGF-1R or IR activity as evidenced by no changes in 
receptor phosphorylation or activation of their key downstream signaling effector 
PI3K in our RPPA dataset. This was confirmed through immunoblot analysis of 
shBECN1 tumors. These findings suggest that IGFBP1 is likely acting 
independently of these receptors. IGFBP1 does have reported functions that are 
independent of its regulation of IGF1 and IGF2 action through their receptors. 
IGFBP1 contains an Arg-Gly-Asp (RDG) motif that promotes interactions with 
integrins287. In fact, IGFBP1 interacts with the α5β1 integrin to promote migration 
in Chinese hamster ovary cells and these same results were seen in human 
trophoblastic cells290,291. Integrins are important for cancer cell interactions and 
expression of integrins, either increased or decreased, can promote tumor 
progression292. These alternative functions of IGFBP1 may play a role in the 
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